CA2373045A1 - Gene therapy using tgf-.beta. - Google Patents
Gene therapy using tgf-.beta. Download PDFInfo
- Publication number
- CA2373045A1 CA2373045A1 CA002373045A CA2373045A CA2373045A1 CA 2373045 A1 CA2373045 A1 CA 2373045A1 CA 002373045 A CA002373045 A CA 002373045A CA 2373045 A CA2373045 A CA 2373045A CA 2373045 A1 CA2373045 A1 CA 2373045A1
- Authority
- CA
- Canada
- Prior art keywords
- tgf
- cells
- beta
- connective tissue
- cell line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001415 gene therapy Methods 0.000 title abstract description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 148
- 238000000034 method Methods 0.000 claims abstract description 77
- 210000000845 cartilage Anatomy 0.000 claims abstract description 38
- 210000003035 hyaline cartilage Anatomy 0.000 claims abstract description 38
- 238000002347 injection Methods 0.000 claims abstract description 35
- 239000007924 injection Substances 0.000 claims abstract description 35
- 230000014509 gene expression Effects 0.000 claims abstract description 28
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 27
- 238000001890 transfection Methods 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 88
- 210000001608 connective tissue cell Anatomy 0.000 claims description 57
- 239000013598 vector Substances 0.000 claims description 38
- 210000002808 connective tissue Anatomy 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 210000002435 tendon Anatomy 0.000 claims description 25
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 21
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 16
- 239000013600 plasmid vector Substances 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 14
- 239000013603 viral vector Substances 0.000 claims description 13
- 206010003246 arthritis Diseases 0.000 claims description 11
- 239000002502 liposome Substances 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 claims description 8
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 8
- 210000001612 chondrocyte Anatomy 0.000 claims description 8
- 239000013612 plasmid Substances 0.000 claims description 8
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 7
- 108010049951 Bone Morphogenetic Protein 3 Proteins 0.000 claims description 7
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 7
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 claims description 7
- 230000001172 regenerating effect Effects 0.000 claims description 7
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 6
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 claims description 6
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 claims description 6
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 6
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims description 6
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 6
- 210000003953 foreskin Anatomy 0.000 claims description 6
- 210000000963 osteoblast Anatomy 0.000 claims description 6
- 230000001177 retroviral effect Effects 0.000 claims description 6
- 239000001506 calcium phosphate Substances 0.000 claims description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 210000001503 joint Anatomy 0.000 claims description 5
- 210000004409 osteocyte Anatomy 0.000 claims description 5
- 238000002054 transplantation Methods 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- 238000000975 co-precipitation Methods 0.000 claims description 4
- 238000005538 encapsulation Methods 0.000 claims description 4
- 210000003041 ligament Anatomy 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 230000002917 arthritic effect Effects 0.000 claims description 3
- 238000004520 electroporation Methods 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 abstract description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 17
- 230000007547 defect Effects 0.000 abstract description 17
- 102000008186 Collagen Human genes 0.000 abstract description 12
- 108010035532 Collagen Proteins 0.000 abstract description 12
- 229920001436 collagen Polymers 0.000 abstract description 12
- 210000001361 achilles tendon Anatomy 0.000 abstract description 11
- 210000000629 knee joint Anatomy 0.000 abstract description 10
- 201000008482 osteoarthritis Diseases 0.000 abstract description 7
- 239000002299 complementary DNA Substances 0.000 abstract description 6
- 230000000399 orthopedic effect Effects 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 239000011159 matrix material Substances 0.000 abstract description 5
- 230000001404 mediated effect Effects 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 4
- 230000001131 transforming effect Effects 0.000 abstract description 3
- 239000013604 expression vector Substances 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 35
- 108020004414 DNA Proteins 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 28
- 239000000047 product Substances 0.000 description 20
- 239000012634 fragment Substances 0.000 description 14
- 230000009471 action Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 210000000988 bone and bone Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 238000001994 activation Methods 0.000 description 6
- 230000003305 autocrine Effects 0.000 description 6
- 210000003321 cartilage cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108090000157 Metallothionein Proteins 0.000 description 5
- 230000022159 cartilage development Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 230000003076 paracrine Effects 0.000 description 5
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 241000269370 Xenopus <genus> Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 4
- 229960001763 zinc sulfate Drugs 0.000 description 4
- 229910000368 zinc sulfate Inorganic materials 0.000 description 4
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 102000003792 Metallothionein Human genes 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 241000906034 Orthops Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000868 anti-mullerian hormone Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000005065 subchondral bone plate Anatomy 0.000 description 3
- 210000001258 synovial membrane Anatomy 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100034581 Dihydroorotase Human genes 0.000 description 2
- 108091000126 Dihydroorotase Proteins 0.000 description 2
- 108700003483 Drosophila dpp Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241001112090 Pseudovirus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- -1 Vgrl Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 230000003848 cartilage regeneration Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000018631 connective tissue disease Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 102100023927 Asparagine synthetase [glutamine-hydrolyzing] Human genes 0.000 description 1
- 102000030907 Aspartate Carbamoyltransferase Human genes 0.000 description 1
- 108010070255 Aspartate-ammonia ligase Proteins 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 206010056809 Bone formation decreased Diseases 0.000 description 1
- 206010061762 Chondropathy Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 101710082464 Cis-aconitate decarboxylase Proteins 0.000 description 1
- 101710147299 DNA fragmentation factor subunit beta Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108700005865 Drosophila gbb Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010090296 Growth Differentiation Factor 1 Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 1
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 1
- 101000851110 Periplaneta americana Vitellogenin-1 Proteins 0.000 description 1
- 101710145525 Probable cinnamyl alcohol dehydrogenase Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000034127 bone morphogenesis Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008367 cartilage synthesis Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000035616 enchondral ossification Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000032631 intramembranous ossification Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000006740 morphological transformation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008142 sex development Effects 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The subject invention is related to a cell-mediated gene therapy treatment f or orthopedic disease using a member belonging to the transforming growth facto r- .beta. (TGF-.beta.) superfamily. TGF-.beta. gene therapy as a new treatment method for degenerative arthritis is demonstrated. After transfection of TGF - .beta. cDNA expression vectors into fibroblasts (NIH 3T3-TGF-.beta.1), the cells were injected into rabbit achilles tendon and knee joints with artificially-made cartilage defects. Intratendinous injections were performe d to determine the optimal concentration for in vivo expression. Partially defected cartilage model was made to simulate degenerative arthritis of the knee joint. The partial cartilage defect treated with the cell-mediated gene therapy procedure was covered by newly formed hyaline cartilage which indicates that the cells survived and stimulated matrix formation in this area. Completely denuded cartilage areas were covered by fibrous collagen.</ SDOAB>
Description
GENE THERAPY USING TGF-(3 BACKGROUND OF THE INVENTION
1. Field of the Invention The present invention relates to a method of introduc ing at least one gene encoding a member of the transforming growth factor (3 superfamily into at least one mammalian connective tissue for use in regenerating connective tissue in the mammalian host. The present invention also relates to a connective tissue cell line that harbors a DNA vector molecule containing a gene encoding a member of the transforming growth factor (3 superfamily.
1. Field of the Invention The present invention relates to a method of introduc ing at least one gene encoding a member of the transforming growth factor (3 superfamily into at least one mammalian connective tissue for use in regenerating connective tissue in the mammalian host. The present invention also relates to a connective tissue cell line that harbors a DNA vector molecule containing a gene encoding a member of the transforming growth factor (3 superfamily.
2. Brief Description of the Related Art In the orthopedic field, degenerative arthritis or osteoarthritis is the most frequently encountered disease associated with cartilage damage. Almost every joint in the body, such as the knee, the hip, the shoulder, and even the wrist, is affected. The pathogenesis of this disease is the degeneration of hyaline articular cartilage (Mankin et al., J
Bone Joint Surg, 52A: 460-466, 1982). The hyaline cartilage of the joint becomes deformed, fibrillated, and eventually excavated. If the degenerated cartilage could somehow be regenerated, most patients would be able to enjoy their lives without debilitating pain. There has been no method reported to date to regenerate damaged hyaline cartilage.
Traditional routes of drug delivery, such as oral, intravenous or intramuscular administration, to carry the drug to the joint are inefficient. The half-life of drugs injected intra-articularly is generally short. Another disadvantage of intra-articular injection of drugs is that frequent repeated injections are necessary to obtain acceptable drug levels at the joint spaces for treating a chronic condition such as arthritis. Because therapeutic agents heretofore could not be selectively targeted to joints, it was necessary to expose the mammalian host to systemically high concentrations of drugs in order to achieve a sustained, intra-articular therapeutic dose.
Exposure of non-target organs in this manner exacerbated the tendency of anti-arthritis drugs to produce serious side effects, such as gastrointestinal upset and changes in the hematological, cardiovascular, hepatic and renal systems of the mammalian host.
In the orthopedic field, some cytokines have been considered as candidates for the treatment of orthopedic diseases. Bone morphogenic protein has been considered to be an effective stimulator of bone formation (Ozkaynak et al., EMBO J, 9:2085-2093, 1990; Sampath and Rueger, Complications in Ortho, 101-107, 1994), and TGF-~3 has been reported as a stimulator of osteogenesis and chondrogenesis (Joyce et al., J Cell Biology, 110:2195-2207, 1990).
Transforming growth factor-(3 (TGF-(3) is consider to be a multifunctional cytokine (Sporn and Roberts, Nature (London), 332: 217-219, 1988), and plays a regulatory role in cellular growth, differentiation and extracellular matrix protein synthesis (Madri et al., J Cell Biology, 106: 1375 1384, 1988). TGF-(3 inhibits the growth of epithelial cells and osteoclast-like cells in vitro (Chenu et al., Proc Natl Acad Sci, 85: 5683-5687, 1988), but it stimulates enchondral ossification and eventually bone formation in vivo (Critchlow et al., Bone, 521-527, 1995; Lind et al., A Orthop Scand, 64(5): 553-556, 1993; and Matsumoto et al., In vivo, 8: 215-220, 1994). TGF-(3-induced bone formation is mediated by its stimulation of the subperiosteal pluripotential cells, which eventually differentiate into cartilage-forming cells (Joyce
Bone Joint Surg, 52A: 460-466, 1982). The hyaline cartilage of the joint becomes deformed, fibrillated, and eventually excavated. If the degenerated cartilage could somehow be regenerated, most patients would be able to enjoy their lives without debilitating pain. There has been no method reported to date to regenerate damaged hyaline cartilage.
Traditional routes of drug delivery, such as oral, intravenous or intramuscular administration, to carry the drug to the joint are inefficient. The half-life of drugs injected intra-articularly is generally short. Another disadvantage of intra-articular injection of drugs is that frequent repeated injections are necessary to obtain acceptable drug levels at the joint spaces for treating a chronic condition such as arthritis. Because therapeutic agents heretofore could not be selectively targeted to joints, it was necessary to expose the mammalian host to systemically high concentrations of drugs in order to achieve a sustained, intra-articular therapeutic dose.
Exposure of non-target organs in this manner exacerbated the tendency of anti-arthritis drugs to produce serious side effects, such as gastrointestinal upset and changes in the hematological, cardiovascular, hepatic and renal systems of the mammalian host.
In the orthopedic field, some cytokines have been considered as candidates for the treatment of orthopedic diseases. Bone morphogenic protein has been considered to be an effective stimulator of bone formation (Ozkaynak et al., EMBO J, 9:2085-2093, 1990; Sampath and Rueger, Complications in Ortho, 101-107, 1994), and TGF-~3 has been reported as a stimulator of osteogenesis and chondrogenesis (Joyce et al., J Cell Biology, 110:2195-2207, 1990).
Transforming growth factor-(3 (TGF-(3) is consider to be a multifunctional cytokine (Sporn and Roberts, Nature (London), 332: 217-219, 1988), and plays a regulatory role in cellular growth, differentiation and extracellular matrix protein synthesis (Madri et al., J Cell Biology, 106: 1375 1384, 1988). TGF-(3 inhibits the growth of epithelial cells and osteoclast-like cells in vitro (Chenu et al., Proc Natl Acad Sci, 85: 5683-5687, 1988), but it stimulates enchondral ossification and eventually bone formation in vivo (Critchlow et al., Bone, 521-527, 1995; Lind et al., A Orthop Scand, 64(5): 553-556, 1993; and Matsumoto et al., In vivo, 8: 215-220, 1994). TGF-(3-induced bone formation is mediated by its stimulation of the subperiosteal pluripotential cells, which eventually differentiate into cartilage-forming cells (Joyce
3 et al., J Cell Biology, 110: 2195-2207, 1990; and Miettinen et al., J Cell Biology, 127-6: 2021-2036, 1994).
The biological effect of TGF-(3 in orthopedics has been reported (Andrew et al., Calcif Tissue In. 52: 74-78, 1993;
Borque et al., Int J Dev Biol., 37:573-579, 1993; Carrington et al., J Cell Biology, 107:1969-1975, 1988; Lind et al., A
Orthop Scand. 64 (5) :553-556, 1993; Matsumoto et al., In vivo, 8:215-220, 1994). In mouse embryos, staining shows that TGF-(3 is closely associated with tissues derived from the mesenchyme, such as connective tissue, cartilage and bone. In addition to embryologic findings, TGF-(3 is present at the site of bone formation and cartilage formation. It can also enhance fracture healing in rabbit tibiae. Recently, the therapeutic value of TGF-(3 has been reported (Critchlow et al., Bone, 521-527, 1995; and Lind et al., A Orthop Scand, 64(5): 553-556, 1993), but its short- term effects and high cost have limited wide clinical application.
Intraarticular injection of TGF-(3 for the treatment of arthritis is not desirable, because the injected TGF-[3 has a short duration of action, as TGF-~ is degradE:=c~. into inactive form in vivo. Therefore, a new method for long-term release of TGF-(3 is necessary for the regeneration of hyaline cartilage.
There have been reports of regeneration of articular cartilage with autotransplantation of cartilage cells (Brittberg et al., New Engl J Med 331: 889-895, 1994), but this procedure entails two operations with wide excision of soft tissues. If intraarticular injection is enough for the treatment of degenerative arthritis, it will be of great economic and physical benefit to the patients.
The biological effect of TGF-(3 in orthopedics has been reported (Andrew et al., Calcif Tissue In. 52: 74-78, 1993;
Borque et al., Int J Dev Biol., 37:573-579, 1993; Carrington et al., J Cell Biology, 107:1969-1975, 1988; Lind et al., A
Orthop Scand. 64 (5) :553-556, 1993; Matsumoto et al., In vivo, 8:215-220, 1994). In mouse embryos, staining shows that TGF-(3 is closely associated with tissues derived from the mesenchyme, such as connective tissue, cartilage and bone. In addition to embryologic findings, TGF-(3 is present at the site of bone formation and cartilage formation. It can also enhance fracture healing in rabbit tibiae. Recently, the therapeutic value of TGF-(3 has been reported (Critchlow et al., Bone, 521-527, 1995; and Lind et al., A Orthop Scand, 64(5): 553-556, 1993), but its short- term effects and high cost have limited wide clinical application.
Intraarticular injection of TGF-(3 for the treatment of arthritis is not desirable, because the injected TGF-[3 has a short duration of action, as TGF-~ is degradE:=c~. into inactive form in vivo. Therefore, a new method for long-term release of TGF-(3 is necessary for the regeneration of hyaline cartilage.
There have been reports of regeneration of articular cartilage with autotransplantation of cartilage cells (Brittberg et al., New Engl J Med 331: 889-895, 1994), but this procedure entails two operations with wide excision of soft tissues. If intraarticular injection is enough for the treatment of degenerative arthritis, it will be of great economic and physical benefit to the patients.
4 Gene therapy, which is a method of transferring a specific protein to a specific site, may be the answer to this problem (Wolff and Lederberg, Gene Therapeutics ed. Jon A. Wolff, 3-25, 1994; and Jenks, J Natl Cancer Inst, 89(16):
1182-1184, 1997).
United States Patents 5,858,355 and 5,766,585 disclose making a viral or plasmid construct of the IRAP
(interleukin-1 receptor antagonist protein) gene;
transfecting synovial cells (5,858,355) and bone marrow cells (5,766,585) with the construct; and injecting the transfected cells into a rabbit joint, but there is no disclosure of using a gene belonging to the TGF-~3 superfamily to regenerate connective tissue.
United States Patents 5,846,931 and 5,700,774 disclose injecting a composition that includes a bone morphogenesis protein (BMP), which belongs to the TGF ~i "superfamily", together with a truncated parathyroid hormone related peptide to effect the maintenance of cartilaginous tissue formation, and induction of cartilaginous tissue. However, there is no disclosure of a gene therapy method using the BMP gene.
In spite of these prior art disclosures, there remains a very real and substantial need for a method of introducing at least one gene encoding a product into at least one cell of a connective tissue of a mammalian host in vitro, or alternatively in vivo, for use in treating the mammalian host. Further, there is a need for a process wherein a gene encoding a member of the transforming growth factor (3 superfamily is used to regenerate connective tissue in the mammalian host. More specifically, there is a need for a process where a gene coding for a TGF-~3 superfamily of proteins is expressed in host connective tissue cells in vi vo .
SUMMARY OF THE INVENTION
The present invention has met the hereinbefore
1182-1184, 1997).
United States Patents 5,858,355 and 5,766,585 disclose making a viral or plasmid construct of the IRAP
(interleukin-1 receptor antagonist protein) gene;
transfecting synovial cells (5,858,355) and bone marrow cells (5,766,585) with the construct; and injecting the transfected cells into a rabbit joint, but there is no disclosure of using a gene belonging to the TGF-~3 superfamily to regenerate connective tissue.
United States Patents 5,846,931 and 5,700,774 disclose injecting a composition that includes a bone morphogenesis protein (BMP), which belongs to the TGF ~i "superfamily", together with a truncated parathyroid hormone related peptide to effect the maintenance of cartilaginous tissue formation, and induction of cartilaginous tissue. However, there is no disclosure of a gene therapy method using the BMP gene.
In spite of these prior art disclosures, there remains a very real and substantial need for a method of introducing at least one gene encoding a product into at least one cell of a connective tissue of a mammalian host in vitro, or alternatively in vivo, for use in treating the mammalian host. Further, there is a need for a process wherein a gene encoding a member of the transforming growth factor (3 superfamily is used to regenerate connective tissue in the mammalian host. More specifically, there is a need for a process where a gene coding for a TGF-~3 superfamily of proteins is expressed in host connective tissue cells in vi vo .
SUMMARY OF THE INVENTION
The present invention has met the hereinbefore
5 described need. A method of introducing at least one gene encoding a product into at least one cell of a mammalian connective tissue for use in treating a mammalian host is provided in the present invention. This method includes employing recombinant techniques to produce a DNA vector molecule containing the gene coding for the product and introducing the DNA vector molecule containing the gene coding for the product into the connective tissue cell. The DNA vector molecule can be any DNA molecule capable of being delivered and maintained within the target cell or tissue such that the gene encoding the product of interest can be stably expressed. The DNA vector molecule preferably utilized in the present invention is either a viral or plasmid DNA vector molecule. This method preferably includes introducing the gene encoding the product into the cell of the mammalian connective tissue for a therapeutic use.
The present invention is directed to a method of treating arthritis comprising:
a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;
b) transfecting in vitro a population of cultured connective tissue cells with said recombinant vector, resulting in a population of transfected connective tissue cells; and
The present invention is directed to a method of treating arthritis comprising:
a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;
b) transfecting in vitro a population of cultured connective tissue cells with said recombinant vector, resulting in a population of transfected connective tissue cells; and
6 c) transplanting the transfected connective tissue cells by intraarticular injection to an arthritic joint space of a mammalian host, such that expression of the DNA
sequence within the joint space results in regenerating connective tissue.
The recombinant vector may be, but not limited to, a retroviral vector, preferably a retroviral vector. The vector may also be a plasmid vector.
The method of the invention includes storing a population of transfected connective tissue cells prior to transplantation. The cells may be stored in 10% DMSO under liquid nitrogen prior to transplantation.
The connective tissue cells include, but are not limited to, fibroblast cells, mesenchymal cells, osteoblasts, or chondrocytes. The fibroblast cells may be NIH 3T3 cells or human foreskin fibroblast cells.
The connective tissue includes, but is not limited to, cartilage, ligament, or tendon. The cartilage may be hyaline cartilage.
The method of the present invention uses a member of the transformation growth factor superfamily, which includes transforming growth factor (3 (TGF-~3). The member of the transformation growth factor superfamily may be TGF-(31, TGF-(32, TGF-~i3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7.
Preferably, TGF-(3 is human or porcine TGF-(31, TGF-(32 or TGF-(3 3 .
The present invention is also directed to a method of regenerating hyaline cartilage, comprising:
a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;
sequence within the joint space results in regenerating connective tissue.
The recombinant vector may be, but not limited to, a retroviral vector, preferably a retroviral vector. The vector may also be a plasmid vector.
The method of the invention includes storing a population of transfected connective tissue cells prior to transplantation. The cells may be stored in 10% DMSO under liquid nitrogen prior to transplantation.
The connective tissue cells include, but are not limited to, fibroblast cells, mesenchymal cells, osteoblasts, or chondrocytes. The fibroblast cells may be NIH 3T3 cells or human foreskin fibroblast cells.
The connective tissue includes, but is not limited to, cartilage, ligament, or tendon. The cartilage may be hyaline cartilage.
The method of the present invention uses a member of the transformation growth factor superfamily, which includes transforming growth factor (3 (TGF-~3). The member of the transformation growth factor superfamily may be TGF-(31, TGF-(32, TGF-~i3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7.
Preferably, TGF-(3 is human or porcine TGF-(31, TGF-(32 or TGF-(3 3 .
The present invention is also directed to a method of regenerating hyaline cartilage, comprising:
a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;
7 PCT/IB00/00653 b) transfecting in vitro a population of cultured connective tissue cells with the recombinant vector, resulting in a population of transfected connective tissue cells; and c) transplanting the transfected connective tissue cells by intraarticular injection to joint space of a mammalian host, such that expression of the DNA sequence within the joint space results in regenerating hyaline cartilage.
The transfection method may be accomplished by methods such as liposome encapsulation, calcium phosphate coprecipitation, electroporation and DEAE-dextran mediation.
The method of the invention includes using preferably the plasmid pmT(31.
The present invention is also directed to a connective tissue cell line comprising a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of the transforming growth factor superfamily. The connective tissue cell line may include, but is not limited to, a fibroblast cell line, a mesenchymal cell line, a chondrocyte cell line, an osteoblast cell line, or are osteocyte cell line. The fibroblast cell line may be a human foreskin fibroblast cell line or NIH 3T3 cell line.
The connective tissue cell line according to the invention comprises a member of the transforming growth factor superfamily. Preferably, a member of the transforming growth factor superfamily is TGF-ail, TGF-~i2, TGF-X33, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7. More preferably, the member is human or porcine TGF-(31, TGF-(32 or TGF-~i3.
The connective tissue cell line of the invention also may comprise cells harboring the recombinant vector pmT(31.
The transfection method may be accomplished by methods such as liposome encapsulation, calcium phosphate coprecipitation, electroporation and DEAE-dextran mediation.
The method of the invention includes using preferably the plasmid pmT(31.
The present invention is also directed to a connective tissue cell line comprising a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of the transforming growth factor superfamily. The connective tissue cell line may include, but is not limited to, a fibroblast cell line, a mesenchymal cell line, a chondrocyte cell line, an osteoblast cell line, or are osteocyte cell line. The fibroblast cell line may be a human foreskin fibroblast cell line or NIH 3T3 cell line.
The connective tissue cell line according to the invention comprises a member of the transforming growth factor superfamily. Preferably, a member of the transforming growth factor superfamily is TGF-ail, TGF-~i2, TGF-X33, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7. More preferably, the member is human or porcine TGF-(31, TGF-(32 or TGF-~i3.
The connective tissue cell line of the invention also may comprise cells harboring the recombinant vector pmT(31.
8 These and other objects of the invention will be more fully understood from the following description of the invention, the referenced drawings attached hereto and the claims appended hereto.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 - Expression of TGF-(31 mRNA. Total RNA was isolated from NIH 3T3 cells or NIH 3T3 cells stably transfected with pmT(31, a TGF-X31 expression vector, which were grown in the absence or presence of zinc. Total RNA (15 mg) was probed with either the TGF-(31 cDNA or (3 actin cDNA as a control.
Figs. 2A-2B - Gross findings of regenerated cartilage.
2A. A rectangular partial cartilage defect was made on the femoral condyle and the knee joint was injected with NIH 3T3 cells without TGF-(31 transfection. The defect was not covered.
2B. At 6 weeks after injection of NIH 3T3-TGF-(31 cells, the defect was covered by newly formed tissue. The color of the regenerated tissue was almost identical to that of the surrounding cartilage.
Fig. 3A-3D - Microscopic findings of regenerated cartilage (X 200).
3A and 3B. Hematoxilin-eosine (H&E) analysis of defect area 4 and 6 weeks after injection with control cells.
No tissue covered the initial defect area.
3C and 3D. Hematoxilin-eosine (H&E) analysis of defect area 4 and 6 weeks after injection of TGF-(31-transfected cells. At 4 weeks, partial defect area was covered by hyaline cartilage after injection of TGF-~il-transfected cells. At 4 weeks and 6 weeks after injection,
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 - Expression of TGF-(31 mRNA. Total RNA was isolated from NIH 3T3 cells or NIH 3T3 cells stably transfected with pmT(31, a TGF-X31 expression vector, which were grown in the absence or presence of zinc. Total RNA (15 mg) was probed with either the TGF-(31 cDNA or (3 actin cDNA as a control.
Figs. 2A-2B - Gross findings of regenerated cartilage.
2A. A rectangular partial cartilage defect was made on the femoral condyle and the knee joint was injected with NIH 3T3 cells without TGF-(31 transfection. The defect was not covered.
2B. At 6 weeks after injection of NIH 3T3-TGF-(31 cells, the defect was covered by newly formed tissue. The color of the regenerated tissue was almost identical to that of the surrounding cartilage.
Fig. 3A-3D - Microscopic findings of regenerated cartilage (X 200).
3A and 3B. Hematoxilin-eosine (H&E) analysis of defect area 4 and 6 weeks after injection with control cells.
No tissue covered the initial defect area.
3C and 3D. Hematoxilin-eosine (H&E) analysis of defect area 4 and 6 weeks after injection of TGF-(31-transfected cells. At 4 weeks, partial defect area was covered by hyaline cartilage after injection of TGF-~il-transfected cells. At 4 weeks and 6 weeks after injection,
9 the regenerated tissue became thicker and its height was almost identical to normal cartilage at 6 weeks.
Histologically, the regenerated cartilage (arrow) was identical to the surrounding hyaline cartilage.
Figs. 4A-4B - Immunohistochemical analysis for TGF-(31 expression in rabbit joint x 200.
Brown immunoperoxidase reaction product indicates high levels of recombinant TGF-X31 expression in the NIH 3T3 TGF-(31 cells (4B) .
4A show hyaline cartilage in a rabbit joint injected with control cells.
Figs. 5A-5B - Microscopic findings (X 200) of regenerated tissues with H&E staining (A) and Safranin-O
staining (B).
5A. In the partially damaged area, the regenerated hyaline cartilage is shown by H&E staining (black arrow).
5B. In the completely denuded cartilage area, the regenerated tissue (white arrow) was fibrous collagen.
Fig. 6 - Plasmid map of pmT(31.
Figs. 7A-7D - Gross morphology of rabbit achilles tendon injected with TGF-(31 transfected cells.
7A. Tendon injected with control cells.
7B. Tendon injected with TGF-X31 transfected cells, six weeks after injection.
7C. Cross-sectional view of the tendon pictured in 7A.
7D. Cross-sectional view of the tendon pictured in 7B.
Figs. 8A-8F - Microscopic findings of regenerated tissue in rabbit achilles tendon with H&E staining.
8A, 8B and 8C show tendon injected with control 5 cells 6 weeks after injection. 8A. x50 magnification. 8B.
x200 magnification. 8C. x600 magnification.
8D, 8E and 8F show tendon injected with TGF-(31 transfected cells 6 weeks after injection. 8D. x50 magnification. 8E. x200 magnification. 8F. x600
Histologically, the regenerated cartilage (arrow) was identical to the surrounding hyaline cartilage.
Figs. 4A-4B - Immunohistochemical analysis for TGF-(31 expression in rabbit joint x 200.
Brown immunoperoxidase reaction product indicates high levels of recombinant TGF-X31 expression in the NIH 3T3 TGF-(31 cells (4B) .
4A show hyaline cartilage in a rabbit joint injected with control cells.
Figs. 5A-5B - Microscopic findings (X 200) of regenerated tissues with H&E staining (A) and Safranin-O
staining (B).
5A. In the partially damaged area, the regenerated hyaline cartilage is shown by H&E staining (black arrow).
5B. In the completely denuded cartilage area, the regenerated tissue (white arrow) was fibrous collagen.
Fig. 6 - Plasmid map of pmT(31.
Figs. 7A-7D - Gross morphology of rabbit achilles tendon injected with TGF-(31 transfected cells.
7A. Tendon injected with control cells.
7B. Tendon injected with TGF-X31 transfected cells, six weeks after injection.
7C. Cross-sectional view of the tendon pictured in 7A.
7D. Cross-sectional view of the tendon pictured in 7B.
Figs. 8A-8F - Microscopic findings of regenerated tissue in rabbit achilles tendon with H&E staining.
8A, 8B and 8C show tendon injected with control 5 cells 6 weeks after injection. 8A. x50 magnification. 8B.
x200 magnification. 8C. x600 magnification.
8D, 8E and 8F show tendon injected with TGF-(31 transfected cells 6 weeks after injection. 8D. x50 magnification. 8E. x200 magnification. 8F. x600
10 magnification. The TGF-(31 transfected cells injected into the tendon appear to be more round than the endogenous tendon cells. Fibrous collagen was produced by autocrine and paracrine modes of action, and the tendon was enlarged. The tendon was enlarged after the injection of TGF-(31 transfected cells.
Figs. 9A-9B - Microscopic findings of regenerated tissue in rabbit achilles tendon with H&E staining (A) and immunohistochemical staining (B) with TGF-(31 antibody. Brown immunoperoxidase reaction product indicates high levels of recombinant TGF-X31 expression in the NIH 3T3-TGF-(31 cells.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "patient" includes members of the animal kingdom including but not limited to human beings.
As used herein, the term "mammalian host" includes members of the animal kingdom including but not limited to human beings.
As used herein, the term "connective tissue" is any tissue that connects and supports other tissues or organs,
Figs. 9A-9B - Microscopic findings of regenerated tissue in rabbit achilles tendon with H&E staining (A) and immunohistochemical staining (B) with TGF-(31 antibody. Brown immunoperoxidase reaction product indicates high levels of recombinant TGF-X31 expression in the NIH 3T3-TGF-(31 cells.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, the term "patient" includes members of the animal kingdom including but not limited to human beings.
As used herein, the term "mammalian host" includes members of the animal kingdom including but not limited to human beings.
As used herein, the term "connective tissue" is any tissue that connects and supports other tissues or organs,
11 and includes but is not limited to a ligament, a cartilage, a tendon, a bone, and a synovium of a mammalian host.
As used herein, the term "connective tissue cell" or "'cell of a connective tissue" include cells that are found in the connective tissue, such as fibroblasts, cartilage cells (chondrocytes), and bone cells (osteoblasts/
osteocytes), which secrete collagenous extracellular matrix, as well as fat cells (adipocytes) and smooth muscle cells.
Preferably, the connective tissue cells are fibroblasts, cartilage cells, and bone cells. More preferably, the connective tissue cells are fibroblast cells. Connective tissue cells also include mesenchymal cells which are also known as immature fibroblasts. It will be recognized that the invention can be practiced with a mixed culture of connective tissue cells, as well as cells of a single type.
As used herein, "connective tissue cell line" includes a plurality of connective tissue cells originating from a common parent cell.
As used herein, "hyaline cartilage" refers to the connective tissue covering the joint surface. By way of example only, hyaline cartilage includes, buy.: i.s not limited to, articular cartilage, costal cartilage, and nose cartilage.
In particular, hyaline cartilage is known to be self renewing, responds to alterations, and provides stable movement with less friction. Hyaline cartilage found even within the same joint or among joints varies in thickness, cell density, matrix composition and mechanical properties, yet retains the same general structure and function. Some of the functions of hyaline cartilage include surprising stiffness to compression, resilience, and exceptional
As used herein, the term "connective tissue cell" or "'cell of a connective tissue" include cells that are found in the connective tissue, such as fibroblasts, cartilage cells (chondrocytes), and bone cells (osteoblasts/
osteocytes), which secrete collagenous extracellular matrix, as well as fat cells (adipocytes) and smooth muscle cells.
Preferably, the connective tissue cells are fibroblasts, cartilage cells, and bone cells. More preferably, the connective tissue cells are fibroblast cells. Connective tissue cells also include mesenchymal cells which are also known as immature fibroblasts. It will be recognized that the invention can be practiced with a mixed culture of connective tissue cells, as well as cells of a single type.
As used herein, "connective tissue cell line" includes a plurality of connective tissue cells originating from a common parent cell.
As used herein, "hyaline cartilage" refers to the connective tissue covering the joint surface. By way of example only, hyaline cartilage includes, buy.: i.s not limited to, articular cartilage, costal cartilage, and nose cartilage.
In particular, hyaline cartilage is known to be self renewing, responds to alterations, and provides stable movement with less friction. Hyaline cartilage found even within the same joint or among joints varies in thickness, cell density, matrix composition and mechanical properties, yet retains the same general structure and function. Some of the functions of hyaline cartilage include surprising stiffness to compression, resilience, and exceptional
12 ability to distribute weight loads, ability to minimize peak stress on subchondral bone, and great durability.
Grossly and histologically, hyaline cartilage appears as a slick, firm surface that resists deformation. The extracellular matrix of the cartilage comprises chondrocytes, but lacks blood vessels, lymphatic vessels or nerves. An elaborate, highly ordered structure that maintains interaction between chondrocytes and the matrix serves to maintain the structure and function of the hyaline cartilage, while maintaining a low level of metabolic activity. The reference O'Driscoll, J. Bone Joint Surg., 80A: 1795-1812, 1998 describes the structure and function of hyaline cartilage in detail, which is incorporated herein by reference in its entirety.
As used herein, the "transforming growth factor-~3 (TGF-(3) superfamily" encompasses a group of structurally-related proteins which affect a wide range of differentiation processes during embryonic development. The family includes, Mullerian inhibiting substance (MIS), which is required for normal male sex development (Behringer, et al., Nature, 345:167, 1990), Drosophila decapentaplegic (DPP) gene product, which is required for dorsal-ventral axis formation and morphogenesis of the imaginal disks (Padgett, et al., Nature, 325:81-84, 1987), the Xenopus Vg-1 gene product, which localizes to the vegetal pole of eggs (Weeks, et al., Cell, 51:861-867, 1987), the activins (Mason, et al., Biochem, Biophys. Res. Commun., 135:957-964, 1986), which 'can induce the formation of mesoderm and anterior structures in Xenopus embryos (Thomsen, et al., Cell, 63:485, 1990), and the bone morphogenetic proteins (BMP's, such as BMP-2, 3, 4, 5, 6 and 7, osteogenin, OP-1) which can induce de novo cartilage and bone formation (Sampath, et al., J. Biol.
Grossly and histologically, hyaline cartilage appears as a slick, firm surface that resists deformation. The extracellular matrix of the cartilage comprises chondrocytes, but lacks blood vessels, lymphatic vessels or nerves. An elaborate, highly ordered structure that maintains interaction between chondrocytes and the matrix serves to maintain the structure and function of the hyaline cartilage, while maintaining a low level of metabolic activity. The reference O'Driscoll, J. Bone Joint Surg., 80A: 1795-1812, 1998 describes the structure and function of hyaline cartilage in detail, which is incorporated herein by reference in its entirety.
As used herein, the "transforming growth factor-~3 (TGF-(3) superfamily" encompasses a group of structurally-related proteins which affect a wide range of differentiation processes during embryonic development. The family includes, Mullerian inhibiting substance (MIS), which is required for normal male sex development (Behringer, et al., Nature, 345:167, 1990), Drosophila decapentaplegic (DPP) gene product, which is required for dorsal-ventral axis formation and morphogenesis of the imaginal disks (Padgett, et al., Nature, 325:81-84, 1987), the Xenopus Vg-1 gene product, which localizes to the vegetal pole of eggs (Weeks, et al., Cell, 51:861-867, 1987), the activins (Mason, et al., Biochem, Biophys. Res. Commun., 135:957-964, 1986), which 'can induce the formation of mesoderm and anterior structures in Xenopus embryos (Thomsen, et al., Cell, 63:485, 1990), and the bone morphogenetic proteins (BMP's, such as BMP-2, 3, 4, 5, 6 and 7, osteogenin, OP-1) which can induce de novo cartilage and bone formation (Sampath, et al., J. Biol.
13 Chem., 265:13198, 1990). The TGF-(3 gene products can influence a variety of differentiation processes, including adipogenesis, myogenesis, chondrogenesis, hematopoiesis, and epithelial cell differentiation (for a review, see Massague, Cell 49:437, 1987), which is incorporated herein by reference in its entirety.
The proteins of the TGF-(3 family are initially synthesized as a large precursor protein which subsequently undergoes proteolytic cleavage at a cluster of basic residues approximately 110-140 amino acids from the C-terminus. The C-terminal regions of the proteins are all structurally related and the different family members can be classified into distinct subgroups based on the extent of their homology. Although the homologies within particular subgroups range from 70o to 90% amino acid sequence identity, the homologies between subgroups are significantly lower, generally ranging from only 20o to 500. In each case, the active species appears to be a disulfide-linked dimer of C-terminal fragments. For most of the family members that have been studied, the homodimeric species has been found to be biologically active, but for other family members, like the inhibins (Ung, et al., Nature, 321:779, 1986) and the TGF-~3's (Cheifetz, et al., Cell, 48:409, 1987), heterodimers have also been detected, and these appear to have different biological properties than the respective homodimers.
Members of the superfamily of TGF-(3 genes include TGF-(33, TGF-(i2, TGF-(34 (chicken) , TGF-(31, TGF-(35 (Xenopus) , BMP-2, BMP-4, Drosophila DPP, BMP-5, BMP-6, Vgrl, OP-1/BMP-7, Drosophila 60A, GDF-1, Xenopus Vgf, BMP-3, Inhibin-(3A, Inhibin-(3B, Inhibin-a, and MIS. These genes are discussed in
The proteins of the TGF-(3 family are initially synthesized as a large precursor protein which subsequently undergoes proteolytic cleavage at a cluster of basic residues approximately 110-140 amino acids from the C-terminus. The C-terminal regions of the proteins are all structurally related and the different family members can be classified into distinct subgroups based on the extent of their homology. Although the homologies within particular subgroups range from 70o to 90% amino acid sequence identity, the homologies between subgroups are significantly lower, generally ranging from only 20o to 500. In each case, the active species appears to be a disulfide-linked dimer of C-terminal fragments. For most of the family members that have been studied, the homodimeric species has been found to be biologically active, but for other family members, like the inhibins (Ung, et al., Nature, 321:779, 1986) and the TGF-~3's (Cheifetz, et al., Cell, 48:409, 1987), heterodimers have also been detected, and these appear to have different biological properties than the respective homodimers.
Members of the superfamily of TGF-(3 genes include TGF-(33, TGF-(i2, TGF-(34 (chicken) , TGF-(31, TGF-(35 (Xenopus) , BMP-2, BMP-4, Drosophila DPP, BMP-5, BMP-6, Vgrl, OP-1/BMP-7, Drosophila 60A, GDF-1, Xenopus Vgf, BMP-3, Inhibin-(3A, Inhibin-(3B, Inhibin-a, and MIS. These genes are discussed in
14 Massague, Ann. Rev. Biochem. 67:753-791, 1998, which is incorporated herein by reference in its entirety.
Preferably, the member of the superfamily of TGF-(3 genes is TGF-(3. More preferably, the member is TGF-(31, TGF
(32, TGF-(33, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7.
Even more preferably, the member is human or porcine TGF-Vii.
Still more preferably, the member is human or porcine TGF-(31, TGF-(32, or TGF-X33. Most preferably, the member is human or porcine TGF-(31.
As used herein, "selectable marker" includes a gene product that is expressed by a cell that stably maintains the introduced DNA, and causes the cell to express an altered phenotype such as morphological transformation, or an enzymatic activity. Isolation of cells that express a transfected gene is achieved by introduction into the same cells a second gene that encodes a selectable marker, such as one having an enzymatic activity that confers resistance to an antibiotic or other drug. Examples of selectable markers include, but are not limited to, thymidine kinase, dihydrofolate reductase, aminoglycoside phosphotransferase, which confers resistance to aminoglycoside antibiotics such as kanamycin, neomycin and geneticin, hygromycin B
phosphotransferase, xanthine-guanine phosphoribosyl transferase, CAD (a single protein that possesses the first three enzymatic activities of de novo uridine biosynthesis -carbamyl phosphate synthetase, aspartate transcarbamylase and dihydroorotase), adenosine deaminase, and asparagine synthetase (Sambrook et al. Molecular Cloning, Chapter 16.
1989), incorporated herein by reference in its entirety.
As used herein, a "promoter" can be any sequence of DNA
that is active, and controls transcription in an eucaryotic cell. The promoter may be active in either or both eucaryotic and procaryotic cells. Preferably, the promoter is active in mammalian cells. The promoter may be constitutively expressed or inducible. Preferably, the promoter is inducible. Preferably, the promoter is inducible 5 by an external stimulus. More preferably, the promoter is inducible by hormones or metals. Still more preferably, the promoter is inducible by heavy metals. Most preferably, the promoter is a metallothionein gene promoter. Likewise, "enhancer elements", which also control transcription, can 10 be inserted into the DNA vector construct, and used with the construct of the present invention to enhance the expression of the gene of interest.
As used herein, the term "DC-chol" means a cationic liposome containing cationic cholesterol derivatives. The
Preferably, the member of the superfamily of TGF-(3 genes is TGF-(3. More preferably, the member is TGF-(31, TGF
(32, TGF-(33, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7.
Even more preferably, the member is human or porcine TGF-Vii.
Still more preferably, the member is human or porcine TGF-(31, TGF-(32, or TGF-X33. Most preferably, the member is human or porcine TGF-(31.
As used herein, "selectable marker" includes a gene product that is expressed by a cell that stably maintains the introduced DNA, and causes the cell to express an altered phenotype such as morphological transformation, or an enzymatic activity. Isolation of cells that express a transfected gene is achieved by introduction into the same cells a second gene that encodes a selectable marker, such as one having an enzymatic activity that confers resistance to an antibiotic or other drug. Examples of selectable markers include, but are not limited to, thymidine kinase, dihydrofolate reductase, aminoglycoside phosphotransferase, which confers resistance to aminoglycoside antibiotics such as kanamycin, neomycin and geneticin, hygromycin B
phosphotransferase, xanthine-guanine phosphoribosyl transferase, CAD (a single protein that possesses the first three enzymatic activities of de novo uridine biosynthesis -carbamyl phosphate synthetase, aspartate transcarbamylase and dihydroorotase), adenosine deaminase, and asparagine synthetase (Sambrook et al. Molecular Cloning, Chapter 16.
1989), incorporated herein by reference in its entirety.
As used herein, a "promoter" can be any sequence of DNA
that is active, and controls transcription in an eucaryotic cell. The promoter may be active in either or both eucaryotic and procaryotic cells. Preferably, the promoter is active in mammalian cells. The promoter may be constitutively expressed or inducible. Preferably, the promoter is inducible. Preferably, the promoter is inducible 5 by an external stimulus. More preferably, the promoter is inducible by hormones or metals. Still more preferably, the promoter is inducible by heavy metals. Most preferably, the promoter is a metallothionein gene promoter. Likewise, "enhancer elements", which also control transcription, can 10 be inserted into the DNA vector construct, and used with the construct of the present invention to enhance the expression of the gene of interest.
As used herein, the term "DC-chol" means a cationic liposome containing cationic cholesterol derivatives. The
15 "DC-chol" molecule includes a tertiary amino group, a medium length spacer arm (two atoms) and a carbamoyl linker bond (Gao et al., Biochem. Biophys. Res, Commun., 179:280-285, 1991) .
As used herein, "SF-chol" is defined as a type of cationic liposome.
As used herein, the term "biologically ~a.ctive" used in relation to liposomes denotes the ability to introduce functional DNA and/or proteins into the target cell.
As used herein, the term "biologically active" in reference to a nucleic acid, protein, protein fragment or derivative thereof is defined as an ability of the nucleic acid or amino acid sequence to mimic a known biological function elicited by the wild type form of the nucleic acid or protein.
As used herein, the term "maintenance", when used in the context of liposome delivery, denotes the ability of the introduced DNA to remain present in the cell. When used in
As used herein, "SF-chol" is defined as a type of cationic liposome.
As used herein, the term "biologically ~a.ctive" used in relation to liposomes denotes the ability to introduce functional DNA and/or proteins into the target cell.
As used herein, the term "biologically active" in reference to a nucleic acid, protein, protein fragment or derivative thereof is defined as an ability of the nucleic acid or amino acid sequence to mimic a known biological function elicited by the wild type form of the nucleic acid or protein.
As used herein, the term "maintenance", when used in the context of liposome delivery, denotes the ability of the introduced DNA to remain present in the cell. When used in
16 other contexts, it means the ability of targeted DNA to remain present in the targeted cell or tissue so as to impart a therapeutic effect.
The present invention discloses ex vivo and in vivo techniques for delivery of a DNA sequence of interest to the connective tissue cells of the mammalian host. The ex vivo technique involves culture of target connective tissue cells, in vitro transfection of the DNA sequence, DNA vector or other delivery vehicle of interest into the connective tissue cells, followed by transplantation of the modified connective tissue cells to the target joint of the mammalian host, so as to effect in vivo expression of the gene product of interest.
As an alternative to the in vitro manipulation of fibroblast cells, the gene encoding the product of interest is introduced into liposomes and injected directly into the area of the joint, where the liposomes fuse with the connective tissue cells, resulting in an in vivo gene expression of the gene product belonging to the TGF-~3 superfamily.
As an additional alternative to the in vitro manipulation of connective tissue cells, the gene encoding the product of interest is introduced into the area of the joint as naked DNA. The naked DNA enters the connective tissue cell, resulting in an in vivo gene expression of the gene product belonging to the TGF-~3 superfamily.
One ex vivo method of treating a connective tissue disorder disclosed throughout this specification comprises initially generating a recombinant viral or plasmid vector which contains a DNA sequence encoding a protein or biologically active fragment thereof. This recombinant vector is then used to infect or transfect a population of
The present invention discloses ex vivo and in vivo techniques for delivery of a DNA sequence of interest to the connective tissue cells of the mammalian host. The ex vivo technique involves culture of target connective tissue cells, in vitro transfection of the DNA sequence, DNA vector or other delivery vehicle of interest into the connective tissue cells, followed by transplantation of the modified connective tissue cells to the target joint of the mammalian host, so as to effect in vivo expression of the gene product of interest.
As an alternative to the in vitro manipulation of fibroblast cells, the gene encoding the product of interest is introduced into liposomes and injected directly into the area of the joint, where the liposomes fuse with the connective tissue cells, resulting in an in vivo gene expression of the gene product belonging to the TGF-~3 superfamily.
As an additional alternative to the in vitro manipulation of connective tissue cells, the gene encoding the product of interest is introduced into the area of the joint as naked DNA. The naked DNA enters the connective tissue cell, resulting in an in vivo gene expression of the gene product belonging to the TGF-~3 superfamily.
One ex vivo method of treating a connective tissue disorder disclosed throughout this specification comprises initially generating a recombinant viral or plasmid vector which contains a DNA sequence encoding a protein or biologically active fragment thereof. This recombinant vector is then used to infect or transfect a population of
17 in vitro cultured connective tissue cells, resulting in a population of connective cells containing the vector. These connective tissue cells are then transplanted to a target joint space of a mammalian host, effecting subsequent expression of the protein or protein fragment within the joint space. Expression of this DNA sequence of interest is useful in substantially reducing at least one deleterious joint pathology associated with a connective tissue disorder.
It will be understood by the artisan of ordinary skill that the preferred source of cells for treating a human patient is the patient's own connective tissue cells, such as autologous fibroblast cells.
More specifically, this method includes employing as the gene a gene capable of encoding a member of the transforming growth factor ~3 superfamily, or a biologically active derivative or fragment thereof and a selectable marker, or a biologically active derivative or fragment thereof .
A further embodiment of the present invention includes employing as the gene a gene capable of encoding at least one of a member of transforming growth factor (3 superfamily or a biologically active derivative or fragment thereof, and employing as the DNA plasmid vector any DNA plasmid vector known to one of ordinary skill in the art capable of stable maintenance within the targeted cell or tissue upon delivery, regardless of the method of delivery utilized.
One such method is the direct delivery of the DNA
vector molecule, whether it be a viral or plasmid DNA vector molecule, to the target cell or tissue. This method also includes employing as the gene a gene capable of encoding a
It will be understood by the artisan of ordinary skill that the preferred source of cells for treating a human patient is the patient's own connective tissue cells, such as autologous fibroblast cells.
More specifically, this method includes employing as the gene a gene capable of encoding a member of the transforming growth factor ~3 superfamily, or a biologically active derivative or fragment thereof and a selectable marker, or a biologically active derivative or fragment thereof .
A further embodiment of the present invention includes employing as the gene a gene capable of encoding at least one of a member of transforming growth factor (3 superfamily or a biologically active derivative or fragment thereof, and employing as the DNA plasmid vector any DNA plasmid vector known to one of ordinary skill in the art capable of stable maintenance within the targeted cell or tissue upon delivery, regardless of the method of delivery utilized.
One such method is the direct delivery of the DNA
vector molecule, whether it be a viral or plasmid DNA vector molecule, to the target cell or tissue. This method also includes employing as the gene a gene capable of encoding a
18 member of transforming growth factor (3 superfamily or biologically active derivative or fragment thereof.
Another embodiment of this invention provides a method for introducing at least one gene encoding a product into at least one cell of a connective tissue for use in treating the mammalian host. This method includes employing non-viral means for introducing the gene coding for the product into the connective tissue cell. More specifically, this method includes a liposome encapsulation, calcium phosphate coprecipitation, electroporation, or DEAF-dextran mediation, and includes employing as the gene a gene capable of encoding a member of transforming growth factor superfamily or biologically active derivative or fragment thereof, and a selectable marker, or biologically active derivative or fragment thereof.
Another embodiment of this invention provides an additional method for introducing at least one gene encoding a product into at least one cell of a connective tissue for use in treating the mammalian host. This additional method includes employing the biologic means of utilizing a virus to deliver the DNA vector molecule to the target cell or tissue. Preferably, the virus is a pseudovirus, the genome having been altered such that the pseudovirus is capable only of delivery and stable maintenance within the target cell, but not retaining an ability to replicate within the target cell or tissue. The altered viral genome is further manipulated by recombinant DNA techniques such that the viral genome acts as a DNA vector molecule which contains the heterologous gene of interest to be expressed within the target cell or tissue.
A preferred embodiment of the invention is a method of delivering TGF-~3 to a target joint space by delivering the
Another embodiment of this invention provides a method for introducing at least one gene encoding a product into at least one cell of a connective tissue for use in treating the mammalian host. This method includes employing non-viral means for introducing the gene coding for the product into the connective tissue cell. More specifically, this method includes a liposome encapsulation, calcium phosphate coprecipitation, electroporation, or DEAF-dextran mediation, and includes employing as the gene a gene capable of encoding a member of transforming growth factor superfamily or biologically active derivative or fragment thereof, and a selectable marker, or biologically active derivative or fragment thereof.
Another embodiment of this invention provides an additional method for introducing at least one gene encoding a product into at least one cell of a connective tissue for use in treating the mammalian host. This additional method includes employing the biologic means of utilizing a virus to deliver the DNA vector molecule to the target cell or tissue. Preferably, the virus is a pseudovirus, the genome having been altered such that the pseudovirus is capable only of delivery and stable maintenance within the target cell, but not retaining an ability to replicate within the target cell or tissue. The altered viral genome is further manipulated by recombinant DNA techniques such that the viral genome acts as a DNA vector molecule which contains the heterologous gene of interest to be expressed within the target cell or tissue.
A preferred embodiment of the invention is a method of delivering TGF-~3 to a target joint space by delivering the
19 TGF-~3 gene to the connective tissue of a mammalian host through use of a retroviral vector with the ex vivo technique disclosed within this specification. In other words, a DNA sequence of interest encoding a functional TGF-(3 protein or protein fragment is subcloned into a retroviral vector of choice, the recombinant viral vector is then grown to adequate titer and used to infect in vitro cultured connective tissue cells, and the transduced connective tissue cells, preferably autografted cells, are transplanted into the joint of interest, preferably by intra-articular injection.
Another preferred method of the present invention involves direct in vivo delivery of a TGF-(3 superfamily gene to the connective tissue of a mammalian host through use of either an adenovirus vector, adeno-associated virus (AAV) vector or herpes-simplex virus (HSV) vector. In other words, a DNA sequence of interest encoding a functional TGF-(3 protein or protein fragment is subcloned into the respective viral vector. The TGF-(3 containing viral vector is then grown to adequate titer and directed into the joint space, preferably by intra-articular injection.
Direct intra-articular injection of a DNA molecule containing the gene of interest into the joint results in transfection of the recipient connective tissue cells and hence bypasses the requirement of removal, in vitro culturing, transfection, selection, as well as transplanting the DNA vector containing-fibroblast to promote stable expression of the heterologous gene of interest.
Methods of presenting the DNA molecule to the target connective tissue of the joint includes, but is not limited to, encapsulation of the DNA molecule into cationic liposomes, subcloning the DNA sequence of interest in a retroviral or plasmid vector, or the direct injection of the DNA molecule itself into the joint. The DNA molecule, regardless of the form of presentation to the knee joint, is preferably presented as a DNA vector molecule, either as 5 recombinant viral DNA vector molecule or a recombinant DNA
plasmid vector molecule. Expression of the heterologous gene of interest is ensured by inserting a promoter fragment active in eukaryotic cells directly upstream of the coding region of the heterologous gene. One of ordinary skill in 10 the art may utilize known strategies and techniques of vector construction to ensure appropriate levels of expression subsequent to entry of the DNA molecule into the connective tissue.
In a preferred embodiment, fibroblasts recovered from 15 the knee joint are cultured in vitro for subsequent utilization as a delivery system for gene therapy. It will be apparent that Applicants are not limited to the use of the specific connective tissue disclosed. It would be possible to utilize other tissue sources for in vitro
Another preferred method of the present invention involves direct in vivo delivery of a TGF-(3 superfamily gene to the connective tissue of a mammalian host through use of either an adenovirus vector, adeno-associated virus (AAV) vector or herpes-simplex virus (HSV) vector. In other words, a DNA sequence of interest encoding a functional TGF-(3 protein or protein fragment is subcloned into the respective viral vector. The TGF-(3 containing viral vector is then grown to adequate titer and directed into the joint space, preferably by intra-articular injection.
Direct intra-articular injection of a DNA molecule containing the gene of interest into the joint results in transfection of the recipient connective tissue cells and hence bypasses the requirement of removal, in vitro culturing, transfection, selection, as well as transplanting the DNA vector containing-fibroblast to promote stable expression of the heterologous gene of interest.
Methods of presenting the DNA molecule to the target connective tissue of the joint includes, but is not limited to, encapsulation of the DNA molecule into cationic liposomes, subcloning the DNA sequence of interest in a retroviral or plasmid vector, or the direct injection of the DNA molecule itself into the joint. The DNA molecule, regardless of the form of presentation to the knee joint, is preferably presented as a DNA vector molecule, either as 5 recombinant viral DNA vector molecule or a recombinant DNA
plasmid vector molecule. Expression of the heterologous gene of interest is ensured by inserting a promoter fragment active in eukaryotic cells directly upstream of the coding region of the heterologous gene. One of ordinary skill in 10 the art may utilize known strategies and techniques of vector construction to ensure appropriate levels of expression subsequent to entry of the DNA molecule into the connective tissue.
In a preferred embodiment, fibroblasts recovered from 15 the knee joint are cultured in vitro for subsequent utilization as a delivery system for gene therapy. It will be apparent that Applicants are not limited to the use of the specific connective tissue disclosed. It would be possible to utilize other tissue sources for in vitro
20 culture techniques. The method of using the gene of this invention may be employed both prophylactically and in the therapeutic treatment of arthritis. It will also be apparent that Applicants are not limited to prophylactic or therapeutic applications in treating only the knee joint. It would be possible to utilize the present invention either prophylactically or therapeutically to treat arthritis in any susceptible joint.
In another embodiment of this invention, a compound for parenteral administration to a patient in a therapeutically effective amount is provided that contains a gene encoding a TGF-(3 superfamily protein and a suitable pharmaceutical carrier.
In another embodiment of this invention, a compound for parenteral administration to a patient in a therapeutically effective amount is provided that contains a gene encoding a TGF-(3 superfamily protein and a suitable pharmaceutical carrier.
21 Another embodiment of this invention provides for a compound for parenteral administration to a patient in a prophylactically effective amount that includes a gene encoding a TGF-~i superfamily protein and a suitable pharmaceutical carrier.
A further embodiment of this invention includes the method as hereinbefore described including introducing the gene into the cell in vitro. This method also includes subsequently transplanting the infected cell into the mammalian host. This method includes after effecting the transfecting of the connective tissue cell but before the transplanting of the infected cell into the mammalian host, storing the transfected connective tissue cell. It will be appreciated by those skilled in the art that the infected connective tissue cell may be stored frozen in 10 percent DMSO in liquid nitrogen. This method includes employing a method to substantially prevent the development of arthritis in a mammalian host having a high susceptibility of developing arthritis.
Another embodiment of this invention includes a method of introducing at least one gene encoding a product into at least one cell of a connective tissue of a mammalian host for use in treating the mammalian host as hereinbefore described including effecting in vivo the infection of the cell by introducing the viral vector containing the gene coding for the product directly into the mammalian host.
Preferably, this method includes effecting the direct introduction into the mammalian host by intra-articular injection. This method includes employing the method to substantially prevent a development of arthritis in a mammalian host having a high susceptibility of developing arthritis. This method also includes employing the method on
A further embodiment of this invention includes the method as hereinbefore described including introducing the gene into the cell in vitro. This method also includes subsequently transplanting the infected cell into the mammalian host. This method includes after effecting the transfecting of the connective tissue cell but before the transplanting of the infected cell into the mammalian host, storing the transfected connective tissue cell. It will be appreciated by those skilled in the art that the infected connective tissue cell may be stored frozen in 10 percent DMSO in liquid nitrogen. This method includes employing a method to substantially prevent the development of arthritis in a mammalian host having a high susceptibility of developing arthritis.
Another embodiment of this invention includes a method of introducing at least one gene encoding a product into at least one cell of a connective tissue of a mammalian host for use in treating the mammalian host as hereinbefore described including effecting in vivo the infection of the cell by introducing the viral vector containing the gene coding for the product directly into the mammalian host.
Preferably, this method includes effecting the direct introduction into the mammalian host by intra-articular injection. This method includes employing the method to substantially prevent a development of arthritis in a mammalian host having a high susceptibility of developing arthritis. This method also includes employing the method on
22 an arthritic mammalian host for therapeutic use. Further this method also includes employing the method to repair and regenerate the connective tissue as hereinbefore defined.
It will be appreciated by those skilled in the art, that the viral vectors employing a liposome are not limited by cell division as is required for the retroviruses to effect infection and integration of connective tissue cells.
This method employing non-viral means as hereinbefore described includes employing as the gene a gene capable of encoding a member belonging to the TGF-(3 superfamily and a selectable marker gene, such as an antibiotic resistance gene.
Another embodiment of the present invention is delivery of a DNA sequence encoding a member of the TGF-(3 superfamily to the connective tissue of a mammalian host by any of the methods disclosed within this specification so as to effect in vivo expression of collagen to regenerate connective tissue, such as cartilage.
In a specific method disclosed as an example, and not as a limitation to the present invention, a DNA plasmid vector containing the TGF-(3 coding sequence was ligated downstream of the metallothionein promoter.
Connective tissues are difficult organs to target therapeutically. Intravenous and oral routes of drug delivery that are known in the art provide poor access to these connective tissues and have the disadvantage of exposing the mammalian host body systemically to the therapeutic agent. More specifically, known intra-articular injection of proteins to joints provides direct access to a joint. However, most of the injected drugs in the form of encapsulated proteins have a short intra-articular half-life. The present invention solves these problems by
It will be appreciated by those skilled in the art, that the viral vectors employing a liposome are not limited by cell division as is required for the retroviruses to effect infection and integration of connective tissue cells.
This method employing non-viral means as hereinbefore described includes employing as the gene a gene capable of encoding a member belonging to the TGF-(3 superfamily and a selectable marker gene, such as an antibiotic resistance gene.
Another embodiment of the present invention is delivery of a DNA sequence encoding a member of the TGF-(3 superfamily to the connective tissue of a mammalian host by any of the methods disclosed within this specification so as to effect in vivo expression of collagen to regenerate connective tissue, such as cartilage.
In a specific method disclosed as an example, and not as a limitation to the present invention, a DNA plasmid vector containing the TGF-(3 coding sequence was ligated downstream of the metallothionein promoter.
Connective tissues are difficult organs to target therapeutically. Intravenous and oral routes of drug delivery that are known in the art provide poor access to these connective tissues and have the disadvantage of exposing the mammalian host body systemically to the therapeutic agent. More specifically, known intra-articular injection of proteins to joints provides direct access to a joint. However, most of the injected drugs in the form of encapsulated proteins have a short intra-articular half-life. The present invention solves these problems by
23 introducing into the connective tissue of a mammalian host genes coding for proteins that may be used to treat the mammalian host. More specifically, this invention provides a method for introducing into the connective tissue of a mammalian host genes coding for proteins with anti-arthritic properties.
In the invention, gene therapy was applied to solve the problem of short duration of action and high cost associated with administering TGF-(3. The transfected cells could survive for more than 6 weeks in tissue cultures without morphological change. To determine the viability and duration of action, the cells were injected into rabbit achilles tendon. If the nutritional supply is adequate for the cells in vivo, the cells could survive and produce TGF-(3 for a long enough period of time to stimulate the surrounding cells. The cells were functional in both the intratendinous and intraarticular environment.
The concentration of transfected cells is an important factor for local action. In a previous experiment (Joyce et al., supra, 1990), the dose of TGF-(3 determined the type of tissue formed. In particular, the ratic_~ of cartilage formation to intramembranous bone formation decreased as the dose was lowered. TGF-(3 is also biphasic in stimulation of primary osteoblasts and MC3T3 cells (Centrella et al., Endocrinology, 119:2306-2312, 1986). That is, it can be both stimulatory and inhibitory according to the concentration (Chenu et al., Proc Natl Acad Sci, 85:5683-5687, 1988). In the Examples provided herein, the NIH 3T3-TGF-(31 cells stimulated collagen synthesis in different concentrations of 109, 105, and 106 cells/ml. The tendon was enlarged mostly with the concentration of 106 cells/ml.
In the invention, gene therapy was applied to solve the problem of short duration of action and high cost associated with administering TGF-(3. The transfected cells could survive for more than 6 weeks in tissue cultures without morphological change. To determine the viability and duration of action, the cells were injected into rabbit achilles tendon. If the nutritional supply is adequate for the cells in vivo, the cells could survive and produce TGF-(3 for a long enough period of time to stimulate the surrounding cells. The cells were functional in both the intratendinous and intraarticular environment.
The concentration of transfected cells is an important factor for local action. In a previous experiment (Joyce et al., supra, 1990), the dose of TGF-(3 determined the type of tissue formed. In particular, the ratic_~ of cartilage formation to intramembranous bone formation decreased as the dose was lowered. TGF-(3 is also biphasic in stimulation of primary osteoblasts and MC3T3 cells (Centrella et al., Endocrinology, 119:2306-2312, 1986). That is, it can be both stimulatory and inhibitory according to the concentration (Chenu et al., Proc Natl Acad Sci, 85:5683-5687, 1988). In the Examples provided herein, the NIH 3T3-TGF-(31 cells stimulated collagen synthesis in different concentrations of 109, 105, and 106 cells/ml. The tendon was enlarged mostly with the concentration of 106 cells/ml.
24 In the Examples, the joint was injected with 0.3 ml of 106 cells/ml concentration. The specimens were harvested from 2 weeks to 6 weeks after injection. The environment in the joint is different from that of the tendon. The cells can move freely within the joint. They will move to the area with specific affinity for the cells. The synovium, meniscus and cartilage defect areas are the possible sites for cellular adhesion. At six weeks after injection, the regenerated tissues were observed at the partially and completely damaged cartilage defect areas, but not at the synovium or the meniscus. This specific affinity for the damaged area is another advantage for clinical application. If degenerative arthritis can be cured with just injection of cells into the joint, the patients can be treated conveniently without major surgery.
The TGF-(3 secreted by injected cells can stimulate hyaline cartilage regeneration by two possible ways. One is that the cartilage cells remaining in the damaged area produce the TGF-(3 receptors at their cell surface (Brand et al., J Biol Chem, 270:8274-8284, 1995; Cheifetz et al., Cell, 48:409-415, 1987; Dumont et al., M Cell Endo, 111:57-66, 1995; Lopez-Casillas et al., Cell, 67:785-795, 1991;
Miettinen et al., J Cell Biology, 127:6, 2021-2036, 1994; and Wrana et al., Nature, 370:341-347, 1994). These receptors may have been stimulated by TGF-(3 secreted by injected cells, which adhere to the damaged area. Because TGF-(3 is secreted in a latent form in vivo (Wakefield et al., J Biol Chem, 263, 7646-7654, 1988), the latent TGF-(3 needs an activation process . The other way is that the latent TGF-(3 or the TGF-~3 secreted from the transfected cells may have bound to the TGF-(3 binding protein (LTBT) at the extracellular matrix of WO 00/66177 PCT/IB00/OOb53 partially damaged cartilage layers (Dallas et al., J Cell Biol, 131:539-549, 1995).
Whatever the mechanism of action is, the finding of hyaline cartilage synthesis indicates that a long duration of 5 high TGF-(3 concentration can stimulate hyaline cartilage regeneration. The vehicle for local high concentration may not be the critical factor for local stimulation, but theoretically, the cartilage cell may be the most suitable vehicle for delivering TGF-(3 to damaged areas of the cartilage 10 (Brittberg et al., New Engl J Med 331:889-895, 1994). The collagen bilayer matrix is another possible vehicle for local distribution of transfected cells (Frenkel et al., J Bone J
Surg (Br) 79-B:831-836, 1997).
The properties of newly formed tissue were determined by 15 a histological method. In H&E staining, the newly formed tissue was identical to surrounding hyaline cartilage (Fig.
4). To evaluate the properties of newly formed tissue, the tissues were stained with Safranin-O (Rosenburg, J Bone Joint Surg, 53A:69-82, 1971). In contrast to the white color of 20 fibrous collagen, the newly formed tissue stained red, suggesting that it is hyaline cartilage (Fig. 5).
The cells in the completely damaged area produced fibrous collagen. The surrounding osteoblastic cells may not have been stimulated because of the osteoid matrix barrier to
The TGF-(3 secreted by injected cells can stimulate hyaline cartilage regeneration by two possible ways. One is that the cartilage cells remaining in the damaged area produce the TGF-(3 receptors at their cell surface (Brand et al., J Biol Chem, 270:8274-8284, 1995; Cheifetz et al., Cell, 48:409-415, 1987; Dumont et al., M Cell Endo, 111:57-66, 1995; Lopez-Casillas et al., Cell, 67:785-795, 1991;
Miettinen et al., J Cell Biology, 127:6, 2021-2036, 1994; and Wrana et al., Nature, 370:341-347, 1994). These receptors may have been stimulated by TGF-(3 secreted by injected cells, which adhere to the damaged area. Because TGF-(3 is secreted in a latent form in vivo (Wakefield et al., J Biol Chem, 263, 7646-7654, 1988), the latent TGF-(3 needs an activation process . The other way is that the latent TGF-(3 or the TGF-~3 secreted from the transfected cells may have bound to the TGF-(3 binding protein (LTBT) at the extracellular matrix of WO 00/66177 PCT/IB00/OOb53 partially damaged cartilage layers (Dallas et al., J Cell Biol, 131:539-549, 1995).
Whatever the mechanism of action is, the finding of hyaline cartilage synthesis indicates that a long duration of 5 high TGF-(3 concentration can stimulate hyaline cartilage regeneration. The vehicle for local high concentration may not be the critical factor for local stimulation, but theoretically, the cartilage cell may be the most suitable vehicle for delivering TGF-(3 to damaged areas of the cartilage 10 (Brittberg et al., New Engl J Med 331:889-895, 1994). The collagen bilayer matrix is another possible vehicle for local distribution of transfected cells (Frenkel et al., J Bone J
Surg (Br) 79-B:831-836, 1997).
The properties of newly formed tissue were determined by 15 a histological method. In H&E staining, the newly formed tissue was identical to surrounding hyaline cartilage (Fig.
4). To evaluate the properties of newly formed tissue, the tissues were stained with Safranin-O (Rosenburg, J Bone Joint Surg, 53A:69-82, 1971). In contrast to the white color of 20 fibrous collagen, the newly formed tissue stained red, suggesting that it is hyaline cartilage (Fig. 5).
The cells in the completely damaged area produced fibrous collagen. The surrounding osteoblastic cells may not have been stimulated because of the osteoid matrix barrier to
25 TGF-(3 stimulation. Instead of stimulating surrounding cells, the NIH 3T3-TGF-/31 cells produced the fibrous collagen by autocrine stimulation. The fact that the cells were stimulated by both autocrine and paracrine activation increases the likelihood of treatment of degenerative arthritis with chondrocytes that have been stably transfected with TGF-(31 expression constructs.
26 The cell lines stably transfected with TGF-(31 expression constructs can survive in tendons and knee joints. The cell lines produce fibrous collagen in the tendon and the completely damaged cartilage area. However, the cell lines produce hyaline cartilage in the partially damaged articular cartilage. The mechanism of stimulation by autocrine and paracrine modes of action indicates that gene therapy with a member of the TGF-(3 superfamily of genes is a new treatment method for hyaline cartilage injury.
The inventors made stable fibroblast (NIH 3T3-TGF-(31, and human foreskin fibroblast TGF-(31) cell line by transfecting TGF-X31 expression constructs. These TGF-(3-producing cells maintained high concentration of active TGF-(3 concentration in vivo for a long duration.
The first question to be answered regarding the possibility of gene therapy and, in particular, cell-mediated gene therapy is the viability of the cells in vivo. Even though TGF-(3 can suppress the immune cells in vitro, the cells may not be able to survive in the tissue of other species with highly effective immune surveillance systems. Secondly, the optimum concentration for gene expression in vivo should be evaluated. We injected the cells into rabbit achilles tendon in three different concentrations to answer this question. The concentration of intraarticular injection to be used was determined from the optimal concentration for intratendinous injection. The third question is how the cells stimulate the regeneration of cartilage within the joint.
There are two modes of action for the injected cells.
One is the activation of surrounding cells by secreted TGF-~3 (paracrine activation) (Snyder, Sci Am, 253(4): 132-140, 1985), and the other is self-activation (autocrine
The inventors made stable fibroblast (NIH 3T3-TGF-(31, and human foreskin fibroblast TGF-(31) cell line by transfecting TGF-X31 expression constructs. These TGF-(3-producing cells maintained high concentration of active TGF-(3 concentration in vivo for a long duration.
The first question to be answered regarding the possibility of gene therapy and, in particular, cell-mediated gene therapy is the viability of the cells in vivo. Even though TGF-(3 can suppress the immune cells in vitro, the cells may not be able to survive in the tissue of other species with highly effective immune surveillance systems. Secondly, the optimum concentration for gene expression in vivo should be evaluated. We injected the cells into rabbit achilles tendon in three different concentrations to answer this question. The concentration of intraarticular injection to be used was determined from the optimal concentration for intratendinous injection. The third question is how the cells stimulate the regeneration of cartilage within the joint.
There are two modes of action for the injected cells.
One is the activation of surrounding cells by secreted TGF-~3 (paracrine activation) (Snyder, Sci Am, 253(4): 132-140, 1985), and the other is self-activation (autocrine
27 activation). The concentration of cells may affect the pathways, but the surrounding environment may be the most important factor for the determination of action mode.
Intraarticular joint fluid and the interior of a ligament are two different environments in terms of blood supply, nutritional supply and surrounding cells. The transfected cells were injected into two different environments to find out the mode of action of the cells. The overall purpose of this study was to evaluate TGF-~3-mediated gene therapy for orthopedic diseases and to ascertain the mode of action in vi vo .
The following examples are offered by way of illustration of the present invention, and not by way of limitation.
EXAMPLES
EXAMPLE I - MATERIALS AND METHODS
Plasmid Construction To generate the metallothionein expression construct (pM), the metallothionein I promoter (-660/+63) was generated by polymerase chain amplification using genomic DNA using Xba I and Bam HI restriction sites built into the oligonucleotides used for amplification. The amplified fragment was subcloned into Xba I-Bam HI sites of pBluescript (Stratagene, La Jolla, CA). The plasmid pmT(31 was generated by subcloning a 1.2-kb Bgl II fragment containing the TGF-(31 coding sequence and a growth hormone poly A site at the 3' end into the Bam HI-Sal I sites of pM.
Cell Culture and Transfections - The TGF-(3 cDNA was transfected into fibroblasts (NIH 3T3-TGF-(31) or human foreskin fibroblast/TGF-(31. They were cultured in Dulbecco's
Intraarticular joint fluid and the interior of a ligament are two different environments in terms of blood supply, nutritional supply and surrounding cells. The transfected cells were injected into two different environments to find out the mode of action of the cells. The overall purpose of this study was to evaluate TGF-~3-mediated gene therapy for orthopedic diseases and to ascertain the mode of action in vi vo .
The following examples are offered by way of illustration of the present invention, and not by way of limitation.
EXAMPLES
EXAMPLE I - MATERIALS AND METHODS
Plasmid Construction To generate the metallothionein expression construct (pM), the metallothionein I promoter (-660/+63) was generated by polymerase chain amplification using genomic DNA using Xba I and Bam HI restriction sites built into the oligonucleotides used for amplification. The amplified fragment was subcloned into Xba I-Bam HI sites of pBluescript (Stratagene, La Jolla, CA). The plasmid pmT(31 was generated by subcloning a 1.2-kb Bgl II fragment containing the TGF-(31 coding sequence and a growth hormone poly A site at the 3' end into the Bam HI-Sal I sites of pM.
Cell Culture and Transfections - The TGF-(3 cDNA was transfected into fibroblasts (NIH 3T3-TGF-(31) or human foreskin fibroblast/TGF-(31. They were cultured in Dulbecco's
28 Modified Eagle's Medium (GIBCO-BRL, Rockville, MD) with 10%
concentration of fetal bovine serum. The TGF-(31 cDNA sequence was added into the pmT(31 vector with a metallothionein gene promoter. A neomycin resistance gene sequence was also inserted into the vector.
The calcium phosphate method to insert this vector into the cells was used. To select the cells with the transfected gene sequence, neomycin (300 ~g/ml) was added into the medium.
Then, the surviving colonies were selected and the expression of TGF-(31 mRNA was confirmed by Northern analysis and TGF-X31 ELISA assay (R & D Systems). The cells with TGF-(31 expression were stored in liquid nitrogen and cultured just before the injection.
Northern Blot analysis - Total RNA was isolated from cells with guanidium isothiocyanate/phenol/chloroform. 10 ~.~g of RNA was electrophoresed on a 1.0 % agarose gel containing 0.66M formaldehyde, transferred to a DURALON-UV membrane, and cross linked with a UV STRATALINKER (STRATAGENE). Blots were prehybridized and hybridized in a solution of 1% bovine serum albumin, 7 % (w/v) SDS, 0 . 5 M sodium phosphate, and 1 mM EDTA
at 65°C. Hybridized blots were washed in 0.1 % SDS, 1 X SSC
for 20 minute periods at 50°C before film exposure. RNA blots were hybridized with 32P-labelled cDNA probes for human TGF-(31. A probe for (3-actin was used to control for sample loading.
Injection of cells into rabbit - New Zealand white rabbits weighing 2.0 - 2.5 kg were selected as the animal model. After anesthetization with ketamine and roumpun, each rabbit was draped in a sterile manner. The achilles tendon
concentration of fetal bovine serum. The TGF-(31 cDNA sequence was added into the pmT(31 vector with a metallothionein gene promoter. A neomycin resistance gene sequence was also inserted into the vector.
The calcium phosphate method to insert this vector into the cells was used. To select the cells with the transfected gene sequence, neomycin (300 ~g/ml) was added into the medium.
Then, the surviving colonies were selected and the expression of TGF-(31 mRNA was confirmed by Northern analysis and TGF-X31 ELISA assay (R & D Systems). The cells with TGF-(31 expression were stored in liquid nitrogen and cultured just before the injection.
Northern Blot analysis - Total RNA was isolated from cells with guanidium isothiocyanate/phenol/chloroform. 10 ~.~g of RNA was electrophoresed on a 1.0 % agarose gel containing 0.66M formaldehyde, transferred to a DURALON-UV membrane, and cross linked with a UV STRATALINKER (STRATAGENE). Blots were prehybridized and hybridized in a solution of 1% bovine serum albumin, 7 % (w/v) SDS, 0 . 5 M sodium phosphate, and 1 mM EDTA
at 65°C. Hybridized blots were washed in 0.1 % SDS, 1 X SSC
for 20 minute periods at 50°C before film exposure. RNA blots were hybridized with 32P-labelled cDNA probes for human TGF-(31. A probe for (3-actin was used to control for sample loading.
Injection of cells into rabbit - New Zealand white rabbits weighing 2.0 - 2.5 kg were selected as the animal model. After anesthetization with ketamine and roumpun, each rabbit was draped in a sterile manner. The achilles tendon
29 was exposed, and 0.2 - 0.3 ml of cells with 10q, 105 and 106 cells/ml concentrations were injected into the mid-portion of the tendon. Zinc sulfate was added to the drinking water of the rabbits for the expression of transfected DNA. After determining the optimal concentration with achilles tendon experiments, the intraarticular injection was performed. The knee joint was exposed, and partial and complete cartilage defects were made with a knife. The partial defects were made on the hyaline cartilage layer with caution not to expose the subchondral bone. The complete defects were made to expose the subchondral bone after removing all of the hyaline cartilage. After closing the surgical wound, the cells with 106 cells/ml concentration were injected intraarticularly, and zinc sulfate was added to the drinking water.
Histological examination - After harvesting the tendons and knee joints, the specimens were fixed in formalin and decalcified with nitric acid. They were embedded in a paraffin block and cut into 0.8 ~,m thickness slices.
Hematoxilin-eosine, and Safranin-O staining were utilized to observe the regenerated tissue microscopically.
EXAMPLE II - RESULTS
Stable cell line - Transfection was carried out by using the calcium phosphate coprecipitation method (Fig. 1). About 80% of the surviving colonies expressed the transgene mRNA.
These selected TGF-X31-producing cells were incubated in a zinc sulfate solution. When the cells were cultured in 100 ~,M zinc sulfate solution, they produced mRNA. The TGF-(3 secretion rate was about 32 ng/106cells/24 hr.
Regeneration of Rabbit Articular Cartilage Defect - The rabbit achilles tendons were observed to check the viability of NIH 3T3-TGF-ail cells. At 106 cells/ml concentration, the tendon was grossly thicker than at the other two 5 concentrations of 109 and 105. After making partial and complete cartilage defects, 0.3 ml of 106 cells/ml of the NIH
3T3-TGF-(31 cells were injected into knee joint s The joint was examined 2 to 6 weeks after injection. In partially damaged cartilage, we found newly formed hyaline cartilage; two weeks 10 after injection, hyaline cartilage appeared and six weeks after injection, the cartilage defects were covered by hyaline cartilage (Fig. 2). The thickness of the regenerated cartilage became thicker as time passed (Fig. 3). The injected cells secreted TGF-(31, that could be observed by 15 immunohistochemical staining with TGF-(31 antibody (Fig. 3).
The contralateral side injected with normal fibroblasts without TGF-~31 transfection was not covered by hyaline cartilage. In the partially damaged area, the regenerated hyaline cartilage was colored red in Safranin-O staining 20 (Fig. 4). (The depth of newly formed cartilage was almost the same as that of the defect.) This finding suggests that the injected cells activate the surrounding normal cartilage cells through a paracrine mode of action.
The regenerated tissues in completely damaged cartilage 25 were not hyaline cartilage but fibrous collagen. Their color in Safranin-O staining was white instead of the red color obtained with hyaline cartilage (Fig. 5). The cartilage was covered by fibrous tissue, which means that these cells were activated only by the autocrine mode. The surrounding
Histological examination - After harvesting the tendons and knee joints, the specimens were fixed in formalin and decalcified with nitric acid. They were embedded in a paraffin block and cut into 0.8 ~,m thickness slices.
Hematoxilin-eosine, and Safranin-O staining were utilized to observe the regenerated tissue microscopically.
EXAMPLE II - RESULTS
Stable cell line - Transfection was carried out by using the calcium phosphate coprecipitation method (Fig. 1). About 80% of the surviving colonies expressed the transgene mRNA.
These selected TGF-X31-producing cells were incubated in a zinc sulfate solution. When the cells were cultured in 100 ~,M zinc sulfate solution, they produced mRNA. The TGF-(3 secretion rate was about 32 ng/106cells/24 hr.
Regeneration of Rabbit Articular Cartilage Defect - The rabbit achilles tendons were observed to check the viability of NIH 3T3-TGF-ail cells. At 106 cells/ml concentration, the tendon was grossly thicker than at the other two 5 concentrations of 109 and 105. After making partial and complete cartilage defects, 0.3 ml of 106 cells/ml of the NIH
3T3-TGF-(31 cells were injected into knee joint s The joint was examined 2 to 6 weeks after injection. In partially damaged cartilage, we found newly formed hyaline cartilage; two weeks 10 after injection, hyaline cartilage appeared and six weeks after injection, the cartilage defects were covered by hyaline cartilage (Fig. 2). The thickness of the regenerated cartilage became thicker as time passed (Fig. 3). The injected cells secreted TGF-(31, that could be observed by 15 immunohistochemical staining with TGF-(31 antibody (Fig. 3).
The contralateral side injected with normal fibroblasts without TGF-~31 transfection was not covered by hyaline cartilage. In the partially damaged area, the regenerated hyaline cartilage was colored red in Safranin-O staining 20 (Fig. 4). (The depth of newly formed cartilage was almost the same as that of the defect.) This finding suggests that the injected cells activate the surrounding normal cartilage cells through a paracrine mode of action.
The regenerated tissues in completely damaged cartilage 25 were not hyaline cartilage but fibrous collagen. Their color in Safranin-O staining was white instead of the red color obtained with hyaline cartilage (Fig. 5). The cartilage was covered by fibrous tissue, which means that these cells were activated only by the autocrine mode. The surrounding
30 osteocytes, which can be stimulated by TGF-(3, appeared to have been blocked from being stimulated by TGF-~3 by the presence of
31 a thick calcified bone matrix. The injected cells may have been unable to stimulate the osteocytes because of this barrier.
TGF-X31 transfected cells were injected into rabbit achilles tendon. The tendon so manipulated exhibited a grossly thicker morphology (Fig. 7) than the control tendon.
H&E staining of a section of the tendon showed, under microscopic examination, the injected NIH 3T3-TGF-X31 cells survived and produced fibrous collagen in rabbit achilles tendon (Fig. 8). Microscopic examination of the regenerated tendon tissue stained immunohistochemically with TGF-(31 antibody showed the expression of TGF-(31 in the tendon (Fig.
9) .
Whereas particular embodiments of this invention have been described above for purposes of illustration, it will be evident to those persons skilled in the art that numerous variations of the details of the present invention may be made without departing from the invention as defined in the appended claims.
All of the references cited herein are incorporated by reference in their entirety.
TGF-X31 transfected cells were injected into rabbit achilles tendon. The tendon so manipulated exhibited a grossly thicker morphology (Fig. 7) than the control tendon.
H&E staining of a section of the tendon showed, under microscopic examination, the injected NIH 3T3-TGF-X31 cells survived and produced fibrous collagen in rabbit achilles tendon (Fig. 8). Microscopic examination of the regenerated tendon tissue stained immunohistochemically with TGF-(31 antibody showed the expression of TGF-(31 in the tendon (Fig.
9) .
Whereas particular embodiments of this invention have been described above for purposes of illustration, it will be evident to those persons skilled in the art that numerous variations of the details of the present invention may be made without departing from the invention as defined in the appended claims.
All of the references cited herein are incorporated by reference in their entirety.
32 REFERENCES
Andrew JG, Hoyland J, Andrew SM, Freemont AJ and Marsh D:
Demonstration of TGF-(31 m-RNA by in situ hybridization in normal fracture healing. Calcif Tissue Int, 52: 74-78, 1993.
Bourque WT, Gross M and Hall BK: Expression of four growth factors during fracture repair. Int J Dev Biol, 37: 573-579, 1993.
Brand T and Schneider MD: Inactive type II and type I
receptors: TGF-(3 are dominant inhibitors of TGF-(3 dependent transcription. J Biol Chem, 270: 8274-8284, 1995.
Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O and Peterson L: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. New Engl J Med 331: 889-895, 1994.
Carrington JL, Roberts AB, Flanders KC, Roche NS and Reddi AH: Accumulation, localization and compartmentation of TGF-~3 during enchondral bone development. J Cell Biology, 107:
1969-1975, 1988.
Centrella M, Massague J and Canalis E: Human platelet-derived transforming growth factor-~i stimulates parameters of bone growth in fetal rat calvariae. Endocrinology, 119: 2306-2312, 1986.
Cheifetz S, Weatherbee JA, Tsang MLS, Anderson JK, Lucas R, Massague J: Transforming growth factor beta system, a complex pattern of cross-reactive ligands and receptors.
Cell, 48: 409-415, 1987.
Chenu C, Pfeilschifter J, Mundy GR and Roodman GD: TGF-(3 inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci, 85: 5683-5687,
Andrew JG, Hoyland J, Andrew SM, Freemont AJ and Marsh D:
Demonstration of TGF-(31 m-RNA by in situ hybridization in normal fracture healing. Calcif Tissue Int, 52: 74-78, 1993.
Bourque WT, Gross M and Hall BK: Expression of four growth factors during fracture repair. Int J Dev Biol, 37: 573-579, 1993.
Brand T and Schneider MD: Inactive type II and type I
receptors: TGF-(3 are dominant inhibitors of TGF-(3 dependent transcription. J Biol Chem, 270: 8274-8284, 1995.
Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O and Peterson L: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. New Engl J Med 331: 889-895, 1994.
Carrington JL, Roberts AB, Flanders KC, Roche NS and Reddi AH: Accumulation, localization and compartmentation of TGF-~3 during enchondral bone development. J Cell Biology, 107:
1969-1975, 1988.
Centrella M, Massague J and Canalis E: Human platelet-derived transforming growth factor-~i stimulates parameters of bone growth in fetal rat calvariae. Endocrinology, 119: 2306-2312, 1986.
Cheifetz S, Weatherbee JA, Tsang MLS, Anderson JK, Lucas R, Massague J: Transforming growth factor beta system, a complex pattern of cross-reactive ligands and receptors.
Cell, 48: 409-415, 1987.
Chenu C, Pfeilschifter J, Mundy GR and Roodman GD: TGF-(3 inhibits formation of osteoclast-like cells in long-term human marrow cultures. Proc Natl Acad Sci, 85: 5683-5687,
33 Critchlow MA, Bland YS and Ashhurst DE: The effect of exogenous transforming growth factor-(32 on healing fractures in the rabbit. Bone, 521-527, 1995.
Dallas SL, Miyazono K, Skerry TM, Mundy GR and Bonewald LF:
Dual role for the latent transforming growth factor beta binding protein (LTBP) in storage of latent TGF-~3 in the extracellular matrix and as a structural matrix protein. J
Cell Biol, 131: 539-549, 1995.
Dumont N, O'Connor M and Philip A: Transforming growth factor receptors on human endometrial cells: identification of the type I and II receptors and glycosyl-phosphatidylinositol anchored TGF-~3 binding proteins. M Cell Endo, 111: 57-66, 1995.
Frenkel SR, Toolan B, Menthe D, Pitman MI and Pachence JM:
Chondrocyte transplantation using a collagen bilayer matrix for cartilage repair. J Bone J Surg [Br] 79-B: 831-836, 1997.
Heine UI, Munoz EF, Flanders KC, Ellingsworth LR, Peter Lam H-Y, Thompson NL,Roberts AB and Sporn MB: Role of Transforming Growth Factor-(3 in the development of the mouse embryo. J Cell Biology, 105: 2861-2876, 1987.
Jenks S: Gene therapy: mastering the basics, defining details [news]. J Natl Cancer Inst, 89(16): 1182-1184, 1997.
Joyce ME, Roberts AB, Sporn MB and Bolander ME: Transforming Growth Factor-(3 and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biology, 110: 2195-2207, 1990.
Lind M, Schumacker B, Soballe K, Keller J, Melsen F, and Bunger: Transforming growth factor-(3 enhances fracture healing in rabbit tibiae. A Orthop Stand, 64(5): 553-556, 1993.
Dallas SL, Miyazono K, Skerry TM, Mundy GR and Bonewald LF:
Dual role for the latent transforming growth factor beta binding protein (LTBP) in storage of latent TGF-~3 in the extracellular matrix and as a structural matrix protein. J
Cell Biol, 131: 539-549, 1995.
Dumont N, O'Connor M and Philip A: Transforming growth factor receptors on human endometrial cells: identification of the type I and II receptors and glycosyl-phosphatidylinositol anchored TGF-~3 binding proteins. M Cell Endo, 111: 57-66, 1995.
Frenkel SR, Toolan B, Menthe D, Pitman MI and Pachence JM:
Chondrocyte transplantation using a collagen bilayer matrix for cartilage repair. J Bone J Surg [Br] 79-B: 831-836, 1997.
Heine UI, Munoz EF, Flanders KC, Ellingsworth LR, Peter Lam H-Y, Thompson NL,Roberts AB and Sporn MB: Role of Transforming Growth Factor-(3 in the development of the mouse embryo. J Cell Biology, 105: 2861-2876, 1987.
Jenks S: Gene therapy: mastering the basics, defining details [news]. J Natl Cancer Inst, 89(16): 1182-1184, 1997.
Joyce ME, Roberts AB, Sporn MB and Bolander ME: Transforming Growth Factor-(3 and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biology, 110: 2195-2207, 1990.
Lind M, Schumacker B, Soballe K, Keller J, Melsen F, and Bunger: Transforming growth factor-(3 enhances fracture healing in rabbit tibiae. A Orthop Stand, 64(5): 553-556, 1993.
34 Lopez-Casillas F, Chifetz S, Doody J, Andres JL, Lane WS
Massague J: Structure and expression of the membrane proteoglycan component of the TGF-~i receptor system. Cell, 67: 785-795, 1991.
Madri JA, Pratt BM and Tucker AM: Phenotypic modulation of endothelial cells by Transforming Growth Factor-~3 depends upon the composition and organization of the extracellular matrix. J Cell Biology, 106: 1375-1384, 1988.
Mankin HJ: The response of articular cartilage to mechanical injury. J Bone Joint Surg, 52A: 460-466, 1982.
Massague, Ann. Rev. Biochem. 67:753-791, 1998.
Matsumoto K, Matsunaga S, Imamura T, Ishidou Y, Yosida H
Sakou T: Expression and distribution of transforming growth factor-(3 during fracture healing. In vivo, 8: 215-220, 1994.
Miettinen PJ, Ebner R, Lopez AR and Derynck R: TGF-(3 induced transdifferentiation of mammary epithelial cells to mesenchymal cells : involvement of type I receptors . J Cell Biology, 127-6: 2021-2036, 1994.
O'Driscoll, J. Bone Joint Surg., 80A: 1795-1812, 1998.
Ozkaynak E, Rueger DC, Drier EA, Corbett C and Ridge RJ: OP-1 cDNA encodes an osteogenic protein in the TGF-~i family.
EMBO J, 9: 2085-2093, 1990.
Rosenburg L: Chemical basis for the histological use of Safranin-O in the study of articular cartilage. J Bone Joint Surg, 53A: 69-82, 1971.
Sampath TK, Rueger DC: Structure, function and orthopedic applications of osteogenic protein-1 (OP-1). Complications in Ortho, 101-107, 1994.
Snyder SH: The molecular basis of communication between cells. Sci Am, 253(4): 132-140, 1985.
Sporn MB and Roberts AB: Peptide growth factors are multifunctional. Nature (London), 332: 217-219, 1988.
Wakefield LM, Smith DM, Flanders KC and Sporn MB: Latent transforming growth factor-~3 from human platelets. J Biol 5 Chem, 263, 7646-7654, 1988.
Wolff JA and Lederberg J: A history of gene transfer and therapy. John A. Wolff, Editor. Gene Therapeutics, 3-25, 1994. Birkhauser, Boston.
Wrana JL, Attisano L, Wieser R, Ventura F and Massague J:
10 Mechanism of activation of the TGF-~i receptor. Nature, 370:
341-347, 1994.
Massague J: Structure and expression of the membrane proteoglycan component of the TGF-~i receptor system. Cell, 67: 785-795, 1991.
Madri JA, Pratt BM and Tucker AM: Phenotypic modulation of endothelial cells by Transforming Growth Factor-~3 depends upon the composition and organization of the extracellular matrix. J Cell Biology, 106: 1375-1384, 1988.
Mankin HJ: The response of articular cartilage to mechanical injury. J Bone Joint Surg, 52A: 460-466, 1982.
Massague, Ann. Rev. Biochem. 67:753-791, 1998.
Matsumoto K, Matsunaga S, Imamura T, Ishidou Y, Yosida H
Sakou T: Expression and distribution of transforming growth factor-(3 during fracture healing. In vivo, 8: 215-220, 1994.
Miettinen PJ, Ebner R, Lopez AR and Derynck R: TGF-(3 induced transdifferentiation of mammary epithelial cells to mesenchymal cells : involvement of type I receptors . J Cell Biology, 127-6: 2021-2036, 1994.
O'Driscoll, J. Bone Joint Surg., 80A: 1795-1812, 1998.
Ozkaynak E, Rueger DC, Drier EA, Corbett C and Ridge RJ: OP-1 cDNA encodes an osteogenic protein in the TGF-~i family.
EMBO J, 9: 2085-2093, 1990.
Rosenburg L: Chemical basis for the histological use of Safranin-O in the study of articular cartilage. J Bone Joint Surg, 53A: 69-82, 1971.
Sampath TK, Rueger DC: Structure, function and orthopedic applications of osteogenic protein-1 (OP-1). Complications in Ortho, 101-107, 1994.
Snyder SH: The molecular basis of communication between cells. Sci Am, 253(4): 132-140, 1985.
Sporn MB and Roberts AB: Peptide growth factors are multifunctional. Nature (London), 332: 217-219, 1988.
Wakefield LM, Smith DM, Flanders KC and Sporn MB: Latent transforming growth factor-~3 from human platelets. J Biol 5 Chem, 263, 7646-7654, 1988.
Wolff JA and Lederberg J: A history of gene transfer and therapy. John A. Wolff, Editor. Gene Therapeutics, 3-25, 1994. Birkhauser, Boston.
Wrana JL, Attisano L, Wieser R, Ventura F and Massague J:
10 Mechanism of activation of the TGF-~i receptor. Nature, 370:
341-347, 1994.
Claims (22)
1. A method of treating arthritis comprising:
a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;
b) transfecting in vitro a population of cultured connective tissue cells with said recombinant vector, resulting in a population of transfected connective tissue cells; and c) transplanting said transfected connective tissue cells by intraarticular injection to an arthritic joint space of a mammalian host, such that expression of said DNA
sequence within said joint space results in regenerating connective tissue.
a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;
b) transfecting in vitro a population of cultured connective tissue cells with said recombinant vector, resulting in a population of transfected connective tissue cells; and c) transplanting said transfected connective tissue cells by intraarticular injection to an arthritic joint space of a mammalian host, such that expression of said DNA
sequence within said joint space results in regenerating connective tissue.
2. The method of claim 1, wherein said recombinant viral vector is a retroviral vector.
3. The method of claim 1, wherein said recombinant vector is a plasmid vector.
4. The method of claim 1, wherein said population of transfected connective tissue cells are stored prior to transplantation.
5. The method of claim 4, wherein said population of transfected connective tissue cells are stored in 10% DMSO
under liquid nitrogen prior to transplantation.
under liquid nitrogen prior to transplantation.
6. The method according to claim 1, wherein said connective tissue cells are fibroblast cells, mesenchymal cells, osteoblasts, or chondrocytes.
7. The method according to claim 6, wherein in said fibroblast cells, the fibroblast cells are NIH 3T3 cells or human foreskin fibroblast cells.
8. The method according to claim 1, wherein said connective tissue is a cartilage, ligament, or tendon.
9. The method according to claim 8, wherein in said cartilage, the cartilage is hyaline cartilage.
10. The method according to claim 1, wherein said member of the transformation growth factor superfamily is transforming growth factor .beta. (TGF-.beta.).
11. The method according to claim 1, wherein said member of the transformation growth factor superfamily is TGF-.beta.1, TGF-.beta.2, TGF-.beta.3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7.
12. The method according to claim 10, wherein said TGF-.beta. is human or porcine TGF-.beta.1, TGF-.beta.2 or TGF-.beta.3.
13. A method of regenerating hyaline cartilage, comprising:
a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;
b) transfecting in vitro a population of cultured connective tissue cells with said recombinant vector, resulting in a population of transfected connective tissue cells; and c) transplanting said transfected connective tissue cells by intraarticular injection to joint space of a mammalian host, such that expression of said DNA sequence within said joint space results in regenerating hyaline cartilage.
a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily of proteins operatively linked to a promoter;
b) transfecting in vitro a population of cultured connective tissue cells with said recombinant vector, resulting in a population of transfected connective tissue cells; and c) transplanting said transfected connective tissue cells by intraarticular injection to joint space of a mammalian host, such that expression of said DNA sequence within said joint space results in regenerating hyaline cartilage.
14. The method of claim 1, wherein said transfection is accomplished by liposome encapsulation, calcium phosphate coprecipitation, electroporation and DEAE-dextran mediation.
15. The method of claim 3, wherein said plasmid is pmT.beta.1.
16. A connective tissue cell line comprising a recombinant viral or plasmid vector comprising a DNA
sequence encoding a member of the transforming growth factor superfamily.
sequence encoding a member of the transforming growth factor superfamily.
17. The connective tissue cell line according to claim 16, wherein said connective tissue cell line is a fibroblast cell line, a mesenchymal cell line, a chondrocyte cell line, an osteoblast cell line, or an osteocyte cell line.
18. The connective tissue cell line according to claim 17, wherein in said fibroblast cell line, the fibroblast cell line is human foreskin fibroblast cell line or NIH 3T3 cell line.
19. The connective tissue cell line according to claim 16, wherein said member of the transforming growth factor superfamily is TGF-.beta..
20. The connective tissue cell line according to claim 16, wherein said member of the transforming growth factor superfamily is TGF-.beta.1, TGF-.beta.2, TGF-.beta.3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, or BMP-7.
21. The connective tissue cell line according to claim 19, wherein said TGF-.beta. is human or porcine TGF-.beta.1, TGF-.beta.2 or TGF-.beta.3.
22. The connective tissue cell line according to claim 16, wherein said recombinant vector is pmT.beta.1.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1999/15854 | 1999-05-03 | ||
KR1019990015854A KR20000072904A (en) | 1999-05-03 | 1999-05-03 | An agent for treating ligament damage and repairing articular cartilage defects comprising TGF-β secreting cell |
US09/345,415 | 1999-06-30 | ||
US09/345,415 US6315992B1 (en) | 1999-06-30 | 1999-06-30 | Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1 |
PCT/IB2000/000653 WO2000066177A1 (en) | 1999-05-03 | 2000-05-03 | GENE THERAPY USING TGF-$g(b) |
WOPCT/US00/00653 | 2000-05-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2373045A1 true CA2373045A1 (en) | 2000-11-09 |
CA2373045C CA2373045C (en) | 2016-07-26 |
Family
ID=26635050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2373045A Expired - Lifetime CA2373045C (en) | 1999-05-03 | 2000-05-03 | Gene therapy using tgf-.beta. |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1175228A4 (en) |
JP (3) | JP4592186B2 (en) |
KR (1) | KR100702725B1 (en) |
CN (2) | CN101972275A (en) |
AU (1) | AU778047B2 (en) |
CA (1) | CA2373045C (en) |
WO (1) | WO2000066177A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002243307A1 (en) * | 2000-11-08 | 2002-07-24 | Tissuegene, Inc. | Gene therapy using tgf-beta |
JP4033400B2 (en) * | 2002-03-12 | 2008-01-16 | ティシュージーン,インク | Cartilage regeneration using chondrocytes and TGF-β |
US7005127B2 (en) | 2002-03-29 | 2006-02-28 | Tissuegene, Inc. | Mixed-cell gene therapy |
WO2004004663A2 (en) * | 2002-07-09 | 2004-01-15 | Stryker Corporation | Compositions and methods for ligament growth and repair |
JP2006515765A (en) * | 2002-11-15 | 2006-06-08 | エスディージーアイ・ホールディングス・インコーポレーテッド | Collagen-based materials and methods for treating synovial joints |
JPWO2005073365A1 (en) * | 2004-01-29 | 2007-09-13 | 株式会社 ジャパン・ティッシュ・エンジニアリング | Method of treating cells for transplantation, cell suspension, prosthesis for transplantation, and method of treating damaged site |
WO2009117740A2 (en) * | 2008-03-21 | 2009-09-24 | Tissuegene, Inc. | Treatment of intervertebral disc degeneration |
JP5388233B2 (en) * | 2011-01-19 | 2014-01-15 | 富士ソフト株式会社 | Method for evaluating the cartilage characteristics of regenerated cartilage |
WO2013166156A2 (en) * | 2012-05-01 | 2013-11-07 | The Johns Hopkins University | Compositions and methods for treating or preventing osteoarthritis |
EP3043825A4 (en) | 2013-09-09 | 2017-05-03 | Figene, LLC | Gene therapy for the regeneration of chondrocytes or cartilage type cells |
EP3647782A4 (en) * | 2017-06-30 | 2021-02-24 | Kolon Life Science, Inc. | Method for assessing validity of cell therapy product |
CN113372432A (en) * | 2021-06-15 | 2021-09-10 | 深圳市臻质医疗科技有限公司 | Method for inducing and/or enhancing cartilage injury repair based on chemically modified mRNA coding protein factor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6413511B1 (en) * | 1990-12-20 | 2002-07-02 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide |
US5858355A (en) * | 1990-12-20 | 1999-01-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | IRAP gene as treatment for arthritis |
US5869041A (en) * | 1996-01-12 | 1999-02-09 | The Miriam Hospital | Delivery of bioactive compounds to an organism |
US6077987A (en) * | 1997-09-04 | 2000-06-20 | North Shore-Long Island Jewish Research Institute | Genetic engineering of cells to enhance healing and tissue regeneration |
EP1604674B1 (en) * | 1998-05-01 | 2008-11-19 | University of Pittsburgh | Use of myoblasts in the manufacture of a medicament for treating stress urinary incontinence |
US6315992B1 (en) * | 1999-06-30 | 2001-11-13 | Tissuegene Co. | Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1 |
-
2000
- 2000-05-03 CA CA2373045A patent/CA2373045C/en not_active Expired - Lifetime
- 2000-05-03 JP JP2000615060A patent/JP4592186B2/en not_active Expired - Lifetime
- 2000-05-03 AU AU44242/00A patent/AU778047B2/en not_active Expired
- 2000-05-03 KR KR1020017013987A patent/KR100702725B1/en active IP Right Grant
- 2000-05-03 CN CN2010105280759A patent/CN101972275A/en active Pending
- 2000-05-03 CN CN008070741A patent/CN1371289B/en not_active Expired - Lifetime
- 2000-05-03 EP EP00925522A patent/EP1175228A4/en not_active Ceased
- 2000-05-03 WO PCT/IB2000/000653 patent/WO2000066177A1/en not_active Application Discontinuation
-
2006
- 2006-07-18 JP JP2006195771A patent/JP4188986B2/en not_active Expired - Lifetime
-
2008
- 2008-07-04 JP JP2008176059A patent/JP4547446B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU778047B2 (en) | 2004-11-11 |
CN1371289B (en) | 2013-03-20 |
JP2007008950A (en) | 2007-01-18 |
CN101972275A (en) | 2011-02-16 |
KR100702725B1 (en) | 2007-04-03 |
AU4424200A (en) | 2000-11-17 |
KR20020036943A (en) | 2002-05-17 |
CN1371289A (en) | 2002-09-25 |
JP4547446B2 (en) | 2010-09-22 |
JP2002542801A (en) | 2002-12-17 |
WO2000066177A1 (en) | 2000-11-09 |
JP4188986B2 (en) | 2008-12-03 |
JP2009019039A (en) | 2009-01-29 |
CA2373045C (en) | 2016-07-26 |
JP4592186B2 (en) | 2010-12-01 |
EP1175228A1 (en) | 2002-01-30 |
EP1175228A4 (en) | 2003-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6315992B1 (en) | Generating cartilage in a mammal using fibroblasts transfected with a vector encoding TGF-β-1 | |
US7282200B2 (en) | Mixed-cell gene therapy | |
CA2479042C (en) | Cartilage regeneration using chondrocyte and tgf-.beta. | |
JP4547446B2 (en) | Gene therapy using TGF-β | |
US20220160780A1 (en) | Mixed-cell gene therapy | |
US20080226611A1 (en) | Gene Therapy Using TGF-beta | |
US7338655B1 (en) | Gene therapy using TGF-β | |
US20220193307A1 (en) | Cartilage Regeneration Using Chondrocyte And TGF-Beta | |
US20190224248A1 (en) | Cartilage regeneration using chondrocyte and tgf-beta | |
WO2002055656A2 (en) | GENE THERAPY USING TGF-$g(b) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20200503 |